Loading...

Antoni Ribas

Title(s)Professor, Medicine
SchoolMedicine
Address760 Westwood Plaza 32-144
Los Angeles CA 90024
Phone3102063928
vCardDownload vCard
    Other Positions
    Title(s)Professor, Surgery

    Title(s)Professor, Molecular and Medical Pharmacology


    Collapse Research 
    Collapse Research Activities and Funding
    Combination Therapies to Defeat Melanoma Resistance
    NIH P01CA244118Sep 11, 2020 - Jun 30, 2025
    Role: Principal Investigator
    Nanosystems Biology Cancer Center
    NIH U54CA199090Aug 1, 2020 - Dec 31, 2017
    Role: Co-Principal Investigator
    Immuno-Targeted Therapy for Melanoma
    NIH R35CA197633Sep 9, 2015 - Aug 31, 2022
    Role: Principal Investigator
    Response and Acquired Resistance to PD-1 Blockade
    NIH R01CA199205Jul 1, 2015 - Jun 30, 2016
    Role: Principal Investigator
    Overcoming BRAF-inhibitor Resistance in Melanoma
    NIH P01CA168585Jul 1, 2013 - Jun 30, 2019
    Role: Principal Investigator
    Strategies for Distinguishing Success in Immunotherapy Treatments (PQ20)
    NIH R01CA170689Sep 1, 2012 - Jun 30, 2016
    Role: Co-Principal Investigator
    AFP-Based Immunotherapy for Hepatocellular Carcinoma
    NIH K23CA093376Sep 1, 2002 - Aug 31, 2007
    Role: Principal Investigator
    Academic Training in Medical Oncology
    NIH T32CA009297Jan 26, 1990 - Dec 31, 1994
    Role: Principal Investigator

    Collapse ORNG Applications 
    Collapse Clinical Trials

    Collapse Bibliographic 
    Collapse Publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help. to make corrections and additions.
    Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
    Altmetrics Details PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
    1. Circulating tumour DNA in patients with advanced melanoma treated with dabrafenib or dabrafenib plus trametinib: a clinical validation study. Lancet Oncol. 2021 Feb 12. PMID: 33587894.
      View in: PubMed   Mentions:    Fields:    
    2. How did we get a COVID-19 vaccine in less than one year? Clin Cancer Res. 2021 Feb 04. Wherry EJ, Jaffee EM, Warren N, D'Souza G, Ribas A. PMID: 33542081.
      View in: PubMed   Mentions:    Fields:    
    3. At the Crossroads: COVID-19 and Immune Checkpoint Blockade for Cancer. Cancer Immunol Res. 2021 Jan 15. Garassino MC, Ribas A. PMID: 33452008.
      View in: PubMed   Mentions:    Fields:    
    4. Long-term safety of pembrolizumab monotherapy and relationship with clinical outcome: A landmark analysis in patients with advanced melanoma. Eur J Cancer. 2020 Dec 23; 144:182-191. Robert C, Hwu WJ, Hamid O, Ribas A, Weber JS, Daud AI, Hodi FS, Wolchok JD, Mitchell TC, Hersey P, Dronca R, Joseph RW, Boutros C, Min L, Long GV, Schachter J, Puzanov I, Dummer R, Lin J, Ibrahim N, Diede SJ, Carlino MS, Joshua AM. PMID: 33360855.
      View in: PubMed   Mentions:    Fields:    
    5. Priority COVID-19 Vaccination for Patients with Cancer while Vaccine Supply Is Limited. Cancer Discov. 2020 Dec 19. Ribas A, Sengupta R, Locke T, Zaidi SK, Campbell KM, Carethers JM, Jaffee EM, Wherry EJ, Soria JC, D'Souza G. PMID: 33355178.
      View in: PubMed   Mentions: 1     Fields:    Translation:HumansPHPublic Health
    6. Durable Suppression of Acquired MEK Inhibitor Resistance in Cancer by Sequestering MEK from ERK and Promoting Anti-Tumor T-cell Immunity. Cancer Discov. 2020 Dec 14. Hong A, Piva M, Liu S, Hugo W, Lomeli SH, Zoete V, Randolph CE, Yang Z, Wang Y, Lee JJ, Lo SJ, Sun L, Vega-Crespo A, Garcia AJ, Shackelford DB, Dubinett SM, Scumpia PO, Byrum SD, Tackett AJ, Donahue TR, Michielin O, Holmen SL, Ribas A, Moriceau G, Lo RS. PMID: 33318037.
      View in: PubMed   Mentions:    Fields:    
    7. PD-L1 blockade in combination with inhibition of MAPK oncogenic signaling in patients with advanced melanoma. Nat Commun. 2020 12 07; 11(1):6262. Ribas A, Algazi A, Ascierto PA, Butler MO, Chandra S, Gordon M, Hernandez-Aya L, Lawrence D, Lutzky J, Miller WH, Campbell KM, Delafont B, Marshall S, Mueller N, Robert C. PMID: 33288749.
      View in: PubMed   Mentions: 1     Fields:    Translation:HumansCTClinical Trials
    8. Conserved Interferon-? Signaling Drives Clinical Response to Immune Checkpoint Blockade Therapy in Melanoma. Cancer Cell. 2020 Dec 05. Grasso CS, Tsoi J, Onyshchenko M, Abril-Rodriguez G, Ross-Macdonald P, Wind-Rotolo M, Champhekar A, Medina E, Torrejon DY, Shin DS, Tran P, Kim YJ, Puig-Saus C, Campbell K, Vega-Crespo A, Quist M, Martignier C, Luke JJ, Wolchok JD, Johnson DB, Chmielowski B, Hodi FS, Bhatia S, Sharfman W, Urba WJ, Slingluff CL, Diab A, Haanen JBAG, Algarra SM, Pardoll DM, Anagnostou V, Topalian SL, Velculescu VE, Speiser DE, Kalbasi A, Ribas A. PMID: 33306984.
      View in: PubMed   Mentions:    Fields:    
    9. KEYNOTE-022 part 3: a randomized, double-blind, phase 2 study of pembrolizumab, dabrafenib, and trametinib in BRAF-mutant melanoma. J Immunother Cancer. 2020 Dec; 8(2). Ferrucci PF, Di Giacomo AM, Del Vecchio M, Atkinson V, Schmidt H, Schachter J, Queirolo P, Long GV, Stephens R, Svane IM, Lotem M, Abu-Amna M, Gasal E, Ghori R, Diede SJ, Croydon ES, Ribas A, Ascierto PA. PMID: 33361337.
      View in: PubMed   Mentions:    Fields:    
    10. Precise T cell recognition programs designed by transcriptionally linking multiple receptors. Science. 2020 Nov 27; 370(6520):1099-1104. Williams JZ, Allen GM, Shah D, Sterin IS, Kim KH, Garcia VP, Shavey GE, Yu W, Puig-Saus C, Tsoi J, Ribas A, Roybal KT, Lim WA. PMID: 33243890.
      View in: PubMed   Mentions:    Fields:    Translation:HumansAnimalsCells
    11. Integrative Tumor and Immune Cell Multi-omic Analyses Predict Response to Immune Checkpoint Blockade in Melanoma. Cell Rep Med. 2020 Nov 17; 1(8):100139. Anagnostou V, Bruhm DC, Niknafs N, White JR, Shao XM, Sidhom JW, Stein J, Tsai HL, Wang H, Belcaid Z, Murray J, Balan A, Ferreira L, Ross-Macdonald P, Wind-Rotolo M, Baras AS, Taube J, Karchin R, Scharpf RB, Grasso C, Ribas A, Pardoll DM, Topalian SL, Velculescu VE. PMID: 33294860.
      View in: PubMed   Mentions:
    12. Uncoupling interferon signaling and antigen presentation to overcome immunotherapy resistance due to JAK1 loss in melanoma. Sci Transl Med. 2020 Oct 14; 12(565). Kalbasi A, Tariveranmoshabad M, Hakimi K, Kremer S, Campbell KM, Funes JM, Vega-Crespo A, Parisi G, Champekar A, Nguyen C, Torrejon D, Shin D, Zaretsky JM, Damoiseaux RD, Speiser DE, Lopez-Casas PP, Quintero M, Ribas A. PMID: 33055240.
      View in: PubMed   Mentions:    Fields:    
    13. Key Parameters of Tumor Epitope Immunogenicity Revealed Through a Consortium Approach Improve Neoantigen Prediction. Cell. 2020 Oct 29; 183(3):818-834.e13. Wells DK, van Buuren MM, Dang KK, Hubbard-Lucey VM, Sheehan KCF, Campbell KM, Lamb A, Ward JP, Sidney J, Blazquez AB, Rech AJ, Zaretsky JM, Comin-Anduix B, Ng AHC, Chour W, Yu TV, Rizvi H, Chen JM, Manning P, Steiner GM, Doan XC, Merghoub T, Guinney J, Kolom A, Selinsky C, Ribas A, Hellmann MD, Hacohen N, Sette A, Heath JR, Bhardwaj N, Ramsdell F, Schreiber RD, Schumacher TN, Kvistborg P, Defranoux NA. PMID: 33038342.
      View in: PubMed   Mentions: 1     Fields:    
    14. Continuous versus intermittent BRAF and MEK inhibition in patients with BRAF-mutated melanoma: a randomized phase 2 trial. Nat Med. 2020 10; 26(10):1564-1568. PMID: 33020646.
      View in: PubMed   Mentions: 2     Fields:    Translation:HumansCTClinical Trials
    15. Combined PD-1, BRAF and MEK inhibition in advanced BRAF-mutant melanoma: safety run-in and biomarker cohorts of COMBI-i. Nat Med. 2020 10; 26(10):1557-1563. PMID: 33020648.
      View in: PubMed   Mentions: 1     Fields:    Translation:HumansCTClinical Trials
    16. Autoantibody Landscape in Patients with Advanced Prostate Cancer. Clin Cancer Res. 2020 Dec 01; 26(23):6204-6214. Chen WS, Haynes WA, Waitz R, Kamath K, Vega-Crespo A, Shrestha R, Zhang M, Foye A, Baselga Carretero I, Perez Garcilazo I, Zhang M, Zhao SG, Sjöström M, Quigley DA, Chou J, Beer TM, Rettig M, Gleave M, Evans CP, Lara P, Chi KN, Reiter RE, Alumkal JJ, Ashworth A, Aggarwal R, Small EJ, Daugherty PS, Ribas A, Oh DY, Shon JC, Feng FY. PMID: 32967941.
      View in: PubMed   Mentions:    Fields:    
    17. IL-32? potentiates tumor immunity in melanoma. JCI Insight. 2020 Sep 17; 5(18). Gruber T, Kremenovic M, Sadozai H, Rombini N, Baeriswyl L, Maibach F, Modlin RL, Gilliet M, von Werdt D, Hunger RE, Seyed Jafari SM, Parisi G, Abril-Rodriguez G, Ribas A, Schenk M. PMID: 32841222.
      View in: PubMed   Mentions:    Fields:    
    18. Disparities in Cancer Prevention in the COVID-19 Era. Cancer Prev Res (Phila). 2020 11; 13(11):893-896. Carethers JM, Sengupta R, Blakey R, Ribas A, D'Souza G. PMID: 32943438.
      View in: PubMed   Mentions: 2     Fields:    Translation:HumansCellsPHPublic Health
    19. Conserved Interferon-? Signaling Drives Clinical Response to Immune Checkpoint Blockade Therapy in Melanoma. Cancer Cell. 2020 Oct 12; 38(4):500-515.e3. Grasso CS, Tsoi J, Onyshchenko M, Abril-Rodriguez G, Ross-Macdonald P, Wind-Rotolo M, Champhekar A, Medina E, Torrejon DY, Shin DS, Tran P, Kim YJ, Puig-Saus C, Campbell K, Vega-Crespo A, Quist M, Martignier C, Luke JJ, Wolchok JD, Johnson DB, Chmielowski B, Hodi FS, Bhatia S, Sharfman W, Urba WJ, Slingluff CL, Diab A, Haanen JBAG, Algarra SM, Pardoll DM, Anagnostou V, Topalian SL, Velculescu VE, Speiser DE, Kalbasi A, Ribas A. PMID: 32916126.
      View in: PubMed   Mentions: 1     Fields:    
    20. Impact of initial treatment and prognostic factors on postprogression survival in BRAF-mutated metastatic melanoma treated with dacarbazine or vemurafenib?±?cobimetinib: a pooled analysis of four clinical trials. J Transl Med. 2020 08 03; 18(1):294. Ascierto PA, Ribas A, Larkin J, McArthur GA, Lewis KD, Hauschild A, Flaherty KT, McKenna E, Zhu Q, Mun Y, Dréno B. PMID: 32746839.
      View in: PubMed   Mentions:    Fields:    
    21. Association of BRAF V600E/K Mutation Status and Prior BRAF/MEK Inhibition With Pembrolizumab Outcomes in Advanced Melanoma: Pooled Analysis of 3 Clinical Trials. JAMA Oncol. 2020 08 01; 6(8):1256-1264. Puzanov I, Ribas A, Robert C, Schachter J, Nyakas M, Daud A, Arance A, Carlino MS, O'Day SJ, Long GV, Margolin KA, Dummer R, Schadendorf D, Lutzky J, Ascierto PA, Tarhini A, Lin J, Mogg R, Homet Moreno B, Ibrahim N, Hamid O. PMID: 32672795.
      View in: PubMed   Mentions:    Fields:    
    22. Epigenetic Suppression of Transgenic T-cell Receptor Expression via Gamma-Retroviral Vector Methylation in Adoptive Cell Transfer Therapy. Cancer Discov. 2020 Nov; 10(11):1645-1653. Nowicki TS, Farrell C, Morselli M, Rubbi L, Campbell KM, Macabali MH, Berent-Maoz B, Comin-Anduix B, Pellegrini M, Ribas A. PMID: 32699033.
      View in: PubMed   Mentions:    Fields:    
    23. Long-term Follow-up of Standard-Dose Pembrolizumab Plus Reduced-Dose Ipilimumab in Patients with Advanced Melanoma: KEYNOTE-029 Part 1B. Clin Cancer Res. 2020 Oct 01; 26(19):5086-5091. Carlino MS, Menzies AM, Atkinson V, Cebon JS, Jameson MB, Fitzharris BM, McNeil CM, Hill AG, Ribas A, Atkins MB, Thompson JA, Hwu WJ, Hodi FS, Guminski AD, Kefford R, Wu H, Ibrahim N, Homet Moreno B, Long GV. PMID: 32605909.
      View in: PubMed   Mentions: 2     Fields:    
    24. Triple therapy for BRAFV600-mutated melanoma. Lancet. 2020 06 13; 395(10240):1814-1815. Ribas A. PMID: 32534635.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    25. Overcoming Genetically Based Resistance Mechanisms to PD-1 Blockade. Cancer Discov. 2020 Aug; 10(8):1140-1157. Torrejon DY, Abril-Rodriguez G, Champhekar AS, Tsoi J, Campbell KM, Kalbasi A, Parisi G, Zaretsky JM, Garcia-Diaz A, Puig-Saus C, Cheung-Lau G, Wohlwender T, Krystofinski P, Vega-Crespo A, Lee CM, Mascaro P, Grasso CS, Berent-Maoz B, Comin-Anduix B, Hu-Lieskovan S, Ribas A. PMID: 32467343.
      View in: PubMed   Mentions: 1     Fields:    
    26. Multi-omic single-cell snapshots reveal multiple independent trajectories to drug tolerance in a melanoma cell line. Nat Commun. 2020 05 11; 11(1):2345. Su Y, Ko ME, Cheng H, Zhu R, Xue M, Wang J, Lee JW, Frankiw L, Xu A, Wong S, Robert L, Takata K, Yuan D, Lu Y, Huang S, Ribas A, Levine R, Nolan GP, Wei W, Plevritis SK, Li G, Baltimore D, Heath JR. PMID: 32393797.
      View in: PubMed   Mentions: 3     Fields:    Translation:HumansCells
    27. Trying for a BRAF Slam Dunk. Cancer Discov. 2020 May; 10(5):640-642. Ribas A, Lo RS. PMID: 32357967.
      View in: PubMed   Mentions: 1     Fields:    
    28. Prediction of SARS-CoV-2 epitopes across 9360 HLA class I alleles. bioRxiv. 2020 Apr 01. Campbell KM, Steiner G, Wells DK, Ribas A, Kalbasi A. PMID: 32511325.
      View in: PubMed   Mentions:
    29. Survival of patients with advanced metastatic melanoma: The impact of MAP kinase pathway inhibition and immune checkpoint inhibition - Update 2019. Eur J Cancer. 2020 05; 130:126-138. Ugurel S, Röhmel J, Ascierto PA, Becker JC, Flaherty KT, Grob JJ, Hauschild A, Larkin J, Livingstone E, Long GV, Lorigan P, McArthur GA, Ribas A, Robert C, Zimmer L, Schadendorf D, Garbe C. PMID: 32179447.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    30. Persistence of adoptively transferred T cells with a kinetically engineered IL-2 receptor agonist. Nat Commun. 2020 01 31; 11(1):660. Parisi G, Saco JD, Salazar FB, Tsoi J, Krystofinski P, Puig-Saus C, Zhang R, Zhou J, Cheung-Lau GC, Garcia AJ, Grasso CS, Tavaré R, Hu-Lieskovan S, Mackay S, Zalevsky J, Bernatchez C, Diab A, Wu AM, Comin-Anduix B, Charych D, Ribas A. PMID: 32005809.
      View in: PubMed   Mentions: 5     Fields:    Translation:HumansAnimalsCells
    31. Long-term outcomes in patients with BRAF V600-mutant metastatic melanoma receiving dabrafenib monotherapy: Analysis from phase 2 and 3 clinical trials. Eur J Cancer. 2020 01; 125:114-120. Hauschild A, Ascierto PA, Schadendorf D, Grob JJ, Ribas A, Kiecker F, Dutriaux C, Demidov LV, Lebbé C, Rutkowski P, Blank CU, Gutzmer R, Millward M, Kefford R, Haas T, D'Amelio A, Gasal E, Mookerjee B, Chapman PB. PMID: 31864178.
      View in: PubMed   Mentions: 6     Fields:    Translation:HumansCTClinical Trials
    32. Interferon Receptor Signaling Pathways Regulating PD-L1 and PD-L2 Expression. Cell Rep. 2019 Dec 10; 29(11):3766. Garcia-Diaz A, Shin DS, Moreno BH, Saco J, Escuin-Ordinas H, Rodriguez GA, Zaretsky JM, Sun L, Hugo W, Wang X, Parisi G, Saus CP, Torrejon DY, Graeber TG, Comin-Anduix B, Hu-Lieskovan S, Damoiseaux R, Lo RS, Ribas A. PMID: 31825850.
      View in: PubMed   Mentions: 5     Fields:    
    33. Global alteration of T-lymphocyte metabolism by PD-L1 checkpoint involves a block of de novo nucleoside phosphate synthesis. Cell Discov. 2019; 5:62. Palaskas NJ, Garcia JD, Shirazi R, Shin DS, Puig-Saus C, Braas D, Ribas A, Graeber TG. PMID: 31798961.
      View in: PubMed   Mentions:
    34. Extended 5-Year Follow-up Results of a Phase Ib Study (BRIM7) of Vemurafenib and Cobimetinib in BRAF-Mutant Melanoma. Clin Cancer Res. 2020 01 01; 26(1):46-53. Ribas A, Daud A, Pavlick AC, Gonzalez R, Lewis KD, Hamid O, Gajewski TF, Puzanov I, Wongchenko M, Rooney I, Hsu JJ, Yan Y, Park E, McArthur GA. PMID: 31732523.
      View in: PubMed   Mentions: 1     Fields:    Translation:HumansCTClinical Trials
    35. Genetic Heterogeneity of BRAF Fusion Kinases in Melanoma Affects Drug Responses. Cell Rep. 2019 10 15; 29(3):573-588.e7. Botton T, Talevich E, Mishra VK, Zhang T, Shain AH, Berquet C, Gagnon A, Judson RL, Ballotti R, Ribas A, Herlyn M, Rocchi S, Brown KM, Hayward NK, Yeh I, Bastian BC. PMID: 31618628.
      View in: PubMed   Mentions: 4     Fields:    Translation:HumansAnimalsCells
    36. Tumour-intrinsic resistance to immune checkpoint blockade. Nat Rev Immunol. 2020 01; 20(1):25-39. Kalbasi A, Ribas A. PMID: 31570880.
      View in: PubMed   Mentions: 44     Fields:    Translation:HumansAnimalsCells
    37. Development of Hematopoietic Stem Cell-Engineered Invariant Natural Killer T Cell Therapy for Cancer. Cell Stem Cell. 2019 10 03; 25(4):542-557.e9. Zhu Y, Smith DJ, Zhou Y, Li YR, Yu J, Lee D, Wang YC, Di Biase S, Wang X, Hardoy C, Ku J, Tsao T, Lin LJ, Pham AT, Moon H, McLaughlin J, Cheng D, Hollis RP, Campo-Fernandez B, Urbinati F, Wei L, Pang L, Rezek V, Berent-Maoz B, Macabali MH, Gjertson D, Wang X, Galic Z, Kitchen SG, An DS, Hu-Lieskovan S, Kaplan-Lefko PJ, De Oliveira SN, Seet CS, Larson SM, Forman SJ, Heath JR, Zack JA, Crooks GM, Radu CG, Ribas A, Kohn DB, Witte ON, Yang L. PMID: 31495780.
      View in: PubMed   Mentions: 2     Fields:    Translation:HumansAnimalsCells
    38. Sensitive Detection and Analysis of Neoantigen-Specific T Cell Populations from Tumors and Blood. Cell Rep. 2019 09 03; 28(10):2728-2738.e7. Peng S, Zaretsky JM, Ng AHC, Chour W, Bethune MT, Choi J, Hsu A, Holman E, Ding X, Guo K, Kim J, Xu AM, Heath JE, Noh WJ, Zhou J, Su Y, Lu Y, McLaughlin J, Cheng D, Witte ON, Baltimore D, Ribas A, Heath JR. PMID: 31484081.
      View in: PubMed   Mentions: 8     Fields:    Translation:HumansCells
    39. Impact of depth of response on survival in patients treated with cobimetinib?±?vemurafenib: pooled analysis of BRIM-2, BRIM-3, BRIM-7 and coBRIM. Br J Cancer. 2019 10; 121(7):522-528. Lewis KD, Larkin J, Ribas A, Flaherty KT, McArthur GA, Ascierto PA, Dréno B, Yan Y, Wongchenko M, McKenna E, Zhu Q, Mun Y, Hauschild A. PMID: 31417188.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    40. Publisher Correction: Combined BRAF and MEK inhibition with PD-1 blockade immunotherapy in BRAF-mutant melanoma. Nat Med. 2019 Aug; 25(8):1319. Ribas A, Lawrence D, Atkinson V, Agarwal S, Miller WH, Carlino MS, Fisher R, Long GV, Hodi FS, Tsoi J, Grasso CS, Mookerjee B, Zhao Q, Ghori R, Moreno BH, Ibrahim N, Hamid O. PMID: 31267021.
      View in: PubMed   Mentions: 1     Fields:    
    41. Pembrolizumab versus ipilimumab in advanced melanoma (KEYNOTE-006): post-hoc 5-year results from an open-label, multicentre, randomised, controlled, phase 3 study. Lancet Oncol. 2019 09; 20(9):1239-1251. Robert C, Ribas A, Schachter J, Arance A, Grob JJ, Mortier L, Daud A, Carlino MS, McNeil CM, Lotem M, Larkin JMG, Lorigan P, Neyns B, Blank CU, Petrella TM, Hamid O, Su SC, Krepler C, Ibrahim N, Long GV. PMID: 31345627.
      View in: PubMed   Mentions: 61     Fields:    Translation:HumansCTClinical Trials
    42. Dabrafenib, trametinib and pembrolizumab or placebo in BRAF-mutant melanoma. Nat Med. 2019 06; 25(6):941-946. Ascierto PA, Ferrucci PF, Fisher R, Del Vecchio M, Atkinson V, Schmidt H, Schachter J, Queirolo P, Long GV, Di Giacomo AM, Svane IM, Lotem M, Bar-Sela G, Couture F, Mookerjee B, Ghori R, Ibrahim N, Moreno BH, Ribas A. PMID: 31171878.
      View in: PubMed   Mentions: 32     Fields:    Translation:HumansCTClinical Trials
    43. Combined BRAF and MEK inhibition with PD-1 blockade immunotherapy in BRAF-mutant melanoma. Nat Med. 2019 06; 25(6):936-940. Ribas A, Lawrence D, Atkinson V, Agarwal S, Miller WH, Carlino MS, Fisher R, Long GV, Hodi FS, Tsoi J, Grasso CS, Mookerjee B, Zhao Q, Ghori R, Moreno BH, Ibrahim N, Hamid O. PMID: 31171879.
      View in: PubMed   Mentions: 42     Fields:    Translation:HumansCTClinical Trials
    44. Effect of concomitant dosing with acid-reducing agents and vemurafenib dose on survival in patients with BRAFV600 mutation-positive metastatic melanoma treated with vemurafenib ± cobimetinib. Eur J Cancer. 2019 07; 116:45-55. Lewis K, Hauschild A, Larkin J, Ribas A, Flaherty KT, McArthur GA, Dréno B, McKenna E, Zhu Q, Mun Y, Ascierto PA. PMID: 31173962.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    45. Five-Year Outcomes with Dabrafenib plus Trametinib in Metastatic Melanoma. N Engl J Med. 2019 08 15; 381(7):626-636. Robert C, Grob JJ, Stroyakovskiy D, Karaszewska B, Hauschild A, Levchenko E, Chiarion Sileni V, Schachter J, Garbe C, Bondarenko I, Gogas H, Mandalá M, Haanen JBAG, Lebbé C, Mackiewicz A, Rutkowski P, Nathan PD, Ribas A, Davies MA, Flaherty KT, Burgess P, Tan M, Gasal E, Voi M, Schadendorf D, Long GV. PMID: 31166680.
      View in: PubMed   Mentions: 77     Fields:    Translation:HumansCTClinical Trials
    46. Anti-CTLA-4 Immunotherapy Does Not Deplete FOXP3+ Regulatory T Cells (Tregs) in Human Cancers-Response. Clin Cancer Res. 2019 06 01; 25(11):3469-3470. Sharma A, Subudhi SK, Blando J, Vence L, Wargo J, Allison JP, Ribas A, Sharma P. PMID: 31160495.
      View in: PubMed   Mentions: 9     Fields:    Translation:HumansCells
    47. Tumor Characteristics Associated with Benefit from Pembrolizumab in Advanced Non-Small Cell Lung Cancer. Clin Cancer Res. 2019 08 15; 25(16):5061-5068. Hu-Lieskovan S, Lisberg A, Zaretsky JM, Grogan TR, Rizvi H, Wells DK, Carroll J, Cummings A, Madrigal J, Jones B, Gukasyan J, Shintaku IP, Slamon D, Dubinett S, Goldman JW, Elashoff D, Hellmann MD, Ribas A, Garon EB. PMID: 31113840.
      View in: PubMed   Mentions: 6     Fields:    Translation:Humans
    48. Interleukin 32 expression in human melanoma. J Transl Med. 2019 04 05; 17(1):113. Paz H, Tsoi J, Kalbasi A, Grasso CS, McBride WH, Schaue D, Butterfield LH, Maurer DM, Ribas A, Graeber TG, Economou JS. PMID: 30953519.
      View in: PubMed   Mentions: 1     Fields:    Translation:HumansCells
    49. Adverse events 2.0-Let us get SERIOs: New reporting for adverse event outcomes needed in the era of immunooncology. Eur J Cancer. 2019 05; 112:29-31. Heinzerling L, Ascierto PA, Dummer R, Gogas H, Grob JJ, Lebbe C, Long GV, McArthur G, Moslehi JJ, Neilan TG, Ribas A, Robert C, Schadendorf D, Wolchok JD, Hauschild A. PMID: 30903870.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    50. Autoimmune genetic risk variants as germline biomarkers of response to melanoma immune-checkpoint inhibition. Cancer Immunol Immunother. 2019 Jun; 68(6):897-905. Chat V, Ferguson R, Simpson D, Kazlow E, Lax R, Moran U, Pavlick A, Frederick D, Boland G, Sullivan R, Ribas A, Flaherty K, Osman I, Weber J, Kirchhoff T. PMID: 30863922.
      View in: PubMed   Mentions: 6     Fields:    Translation:HumansCells
    51. Genomic Features of Exceptional Response in Vemurafenib ± Cobimetinib-treated Patients with BRAFV600-mutated Metastatic Melanoma. Clin Cancer Res. 2019 06 01; 25(11):3239-3246. Yan Y, Wongchenko MJ, Robert C, Larkin J, Ascierto PA, Dréno B, Maio M, Garbe C, Chapman PB, Sosman JA, Shi Z, Koeppen H, Hsu JJ, Chang I, Caro I, Rooney I, McArthur GA, Ribas A. PMID: 30824584.
      View in: PubMed   Mentions: 11     Fields:    Translation:Humans
    52. T cell antigen discovery via trogocytosis. Nat Methods. 2019 02; 16(2):183-190. Li G, Bethune MT, Wong S, Joglekar AV, Leonard MT, Wang JK, Kim JT, Cheng D, Peng S, Zaretsky JM, Su Y, Luo Y, Heath JR, Ribas A, Witte ON, Baltimore D. PMID: 30700903.
      View in: PubMed   Mentions: 9     Fields:    Translation:HumansAnimalsCells
    53. T cell antigen discovery via signaling and antigen-presenting bifunctional receptors. Nat Methods. 2019 02; 16(2):191-198. Joglekar AV, Leonard MT, Jeppson JD, Swift M, Li G, Wong S, Peng S, Zaretsky JM, Heath JR, Ribas A, Bethune MT, Baltimore D. PMID: 30700902.
      View in: PubMed   Mentions: 16     Fields:    Translation:HumansCells
    54. A Pilot Trial of the Combination of Transgenic NY-ESO-1-reactive Adoptive Cellular Therapy with Dendritic Cell Vaccination with or without Ipilimumab. Clin Cancer Res. 2019 04 01; 25(7):2096-2108. Nowicki TS, Berent-Maoz B, Cheung-Lau G, Huang RR, Wang X, Tsoi J, Kaplan-Lefko P, Cabrera P, Tran J, Pang J, Macabali M, Garcilazo IP, Carretero IB, Kalbasi A, Cochran AJ, Grasso CS, Hu-Lieskovan S, Chmielowski B, Comin-Anduix B, Singh A, Ribas A. PMID: 30573690.
      View in: PubMed   Mentions: 15     Fields:    Translation:HumansAnimalsCells
    55. Correction: Baseline Tumor Size Is an Independent Prognostic Factor for Overall Survival in Patients with Melanoma Treated with Pembrolizumab. Clin Cancer Res. 2018 Dec 01; 24(23):6098. Joseph RW, Elassaiss-Schaap J, Kefford R, Hwu WJ, Wolchok JD, Joshua AM, Ribas A, Hodi FS, Hamid O, Robert C, Daud A, Dronca R, Hersey P, Weber JS, Patnaik A, de Alwis DP, Perrone A, Zhang J, Kang SP, Ebbinghaus S, Anderson KM, Gangadhar TC. PMID: 30510087.
      View in: PubMed   Mentions: 4     Fields:    
    56. IND-Enabling Studies for a Clinical Trial to Genetically Program a Persistent Cancer-Targeted Immune System. Clin Cancer Res. 2019 02 01; 25(3):1000-1011. Puig-Saus C, Parisi G, Garcia-Diaz A, Krystofinski PE, Sandoval S, Zhang R, Champhekar AS, McCabe J, Cheung-Lau GC, Truong NA, Vega-Crespo A, Komenan MDS, Pang J, Macabali MH, Saco JD, Goodwin JL, Bolon B, Seet CS, Montel-Hagen A, Crooks GM, Hollis RP, Campo-Fernandez B, Bischof D, Cornetta K, Gschweng EH, Adelson C, Nguyen A, Yang L, Witte ON, Baltimore D, Comin-Anduix B, Kohn DB, Wang X, Cabrera P, Kaplan-Lefko PJ, Berent-Maoz B, Ribas A. PMID: 30409823.
      View in: PubMed   Mentions: 1     Fields:    Translation:HumansAnimalsCells
    57. Isolation and characterization of NY-ESO-1-specific T cell receptors restricted on various MHC molecules. Proc Natl Acad Sci U S A. 2018 11 06; 115(45):E10702-E10711. Bethune MT, Li XH, Yu J, McLaughlin J, Cheng D, Mathis C, Moreno BH, Woods K, Knights AJ, Garcia-Diaz A, Wong S, Hu-Lieskovan S, Puig-Saus C, Cebon J, Ribas A, Yang L, Witte ON, Baltimore D. PMID: 30348802.
      View in: PubMed   Mentions: 9     Fields:    Translation:HumansAnimals
    58. Pan-tumor genomic biomarkers for PD-1 checkpoint blockade-based immunotherapy. Science. 2018 10 12; 362(6411). Cristescu R, Mogg R, Ayers M, Albright A, Murphy E, Yearley J, Sher X, Liu XQ, Lu H, Nebozhyn M, Zhang C, Lunceford JK, Joe A, Cheng J, Webber AL, Ibrahim N, Plimack ER, Ott PA, Seiwert TY, Ribas A, McClanahan TK, Tomassini JE, Loboda A, Kaufman D. PMID: 30309915.
      View in: PubMed   Mentions: 206     Fields:    Translation:HumansCells
    59. Modeled Prognostic Subgroups for Survival and Treatment Outcomes in BRAF V600-Mutated Metastatic Melanoma: Pooled Analysis of 4 Randomized Clinical Trials. JAMA Oncol. 2018 10 01; 4(10):1382-1388. Hauschild A, Larkin J, Ribas A, Dréno B, Flaherty KT, Ascierto PA, Lewis KD, McKenna E, Zhu Q, Mun Y, McArthur GA. PMID: 30073321.
      View in: PubMed   Mentions: 14     Fields:    Translation:Humans
    60. Antitumour activity of pembrolizumab in advanced mucosal melanoma: a post-hoc analysis of KEYNOTE-001, 002, 006. Br J Cancer. 2018 09; 119(6):670-674. Hamid O, Robert C, Ribas A, Hodi FS, Walpole E, Daud A, Arance AS, Brown E, Hoeller C, Mortier L, Schachter J, Long J, Ebbinghaus S, Ibrahim N, Butler M. PMID: 30202085.
      View in: PubMed   Mentions: 14     Fields:    Translation:HumansCTClinical Trials
    61. The new era of adjuvant therapies for melanoma. Nat Rev Clin Oncol. 2018 09; 15(9):535-536. Eggermont AMM, Robert C, Ribas A. PMID: 29849093.
      View in: PubMed   Mentions: 8     Fields:    Translation:Humans
    62. SD-101 in Combination with Pembrolizumab in Advanced Melanoma: Results of a Phase Ib, Multicenter Study. Cancer Discov. 2018 10; 8(10):1250-1257. Ribas A, Medina T, Kummar S, Amin A, Kalbasi A, Drabick JJ, Barve M, Daniels GA, Wong DJ, Schmidt EV, Candia AF, Coffman RL, Leung ACF, Janssen RS. PMID: 30154193.
      View in: PubMed   Mentions: 38     Fields:    Translation:HumansCTClinical Trials
    63. Outcomes by line of therapy and programmed death ligand 1 expression in patients with advanced melanoma treated with pembrolizumab or ipilimumab in KEYNOTE-006: A randomised clinical trial. Eur J Cancer. 2018 09; 101:236-243. Carlino MS, Long GV, Schadendorf D, Robert C, Ribas A, Richtig E, Nyakas M, Caglevic C, Tarhini A, Blank C, Hoeller C, Bar-Sela G, Barrow C, Wolter P, Zhou H, Emancipator K, Jensen EH, Ebbinghaus S, Ibrahim N, Daud A. PMID: 30096704.
      View in: PubMed   Mentions: 16     Fields:    Translation:HumansCTClinical Trials
    64. Anti-CTLA-4 Immunotherapy Does Not Deplete FOXP3+ Regulatory T Cells (Tregs) in Human Cancers. Clin Cancer Res. 2019 02 15; 25(4):1233-1238. Sharma A, Subudhi SK, Blando J, Scutti J, Vence L, Wargo J, Allison JP, Ribas A, Sharma P. PMID: 30054281.
      View in: PubMed   Mentions: 39     Fields:    Translation:HumansCells
    65. Reprogramming human T cell function and specificity with non-viral genome targeting. Nature. 2018 07; 559(7714):405-409. Roth TL, Puig-Saus C, Yu R, Shifrut E, Carnevale J, Li PJ, Hiatt J, Saco J, Krystofinski P, Li H, Tobin V, Nguyen DN, Lee MR, Putnam AL, Ferris AL, Chen JW, Schickel JN, Pellerin L, Carmody D, Alkorta-Aranburu G, Del Gaudio D, Matsumoto H, Morell M, Mao Y, Cho M, Quadros RM, Gurumurthy CB, Smith B, Haugwitz M, Hughes SH, Weissman JS, Schumann K, Esensten JH, May AP, Ashworth A, Kupfer GM, Greeley SAW, Bacchetta R, Meffre E, Roncarolo MG, Romberg N, Herold KC, Ribas A, Leonetti MD, Marson A. PMID: 29995861.
      View in: PubMed   Mentions: 73     Fields:    Translation:HumansAnimalsCells
    66. Age Correlates with Response to Anti-PD1, Reflecting Age-Related Differences in Intratumoral Effector and Regulatory T-Cell Populations. Clin Cancer Res. 2018 11 01; 24(21):5347-5356. Kugel CH, Douglass SM, Webster MR, Kaur A, Liu Q, Yin X, Weiss SA, Darvishian F, Al-Rohil RN, Ndoye A, Behera R, Alicea GM, Ecker BL, Fane M, Allegrezza MJ, Svoronos N, Kumar V, Wang DY, Somasundaram R, Hu-Lieskovan S, Ozgun A, Herlyn M, Conejo-Garcia JR, Gabrilovich D, Stone EL, Nowicki TS, Sosman J, Rai R, Carlino MS, Long GV, Marais R, Ribas A, Eroglu Z, Davies MA, Schilling B, Schadendorf D, Xu W, Amaravadi RK, Menzies AM, McQuade JL, Johnson DB, Osman I, Weeraratna AT. PMID: 29898988.
      View in: PubMed   Mentions: 41     Fields:    Translation:HumansAnimalsCells
    67. Immunotherapy Resistance by Inflammation-Induced Dedifferentiation. Cancer Discov. 2018 08; 8(8):935-943. PMID: 29899062.
      View in: PubMed   Mentions: 18     Fields:    Translation:HumansCells
    68. Characterization of Postinfusion Phenotypic Differences in Fresh Versus Cryopreserved TCR Engineered Adoptive Cell Therapy Products. J Immunother. 2018 Jun; 41(5):248-259. PMID: 29470191.
      View in: PubMed   Mentions: 1     Fields:    Translation:HumansCells
    69. Accelerated wound healing by injectable star poly(ethylene glycol)-b-poly(propylene sulfide) scaffolds loaded with poorly water-soluble drugs. J Control Release. 2018 07 28; 282:156-165. Zhu S, Li S, Escuin-Ordinas H, Dimatteo R, Xi W, Ribas A, Segura T. PMID: 29751029.
      View in: PubMed   Mentions: 1     Fields:    Translation:Animals
    70. Anti-PD-1 antibody treatment for melanoma. Lancet Oncol. 2018 05; 19(5):e219. Ribas A, Kirkwood JM, Flaherty KT. PMID: 29726378.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    71. Baseline Tumor Size Is an Independent Prognostic Factor for Overall Survival in Patients with Melanoma Treated with Pembrolizumab. Clin Cancer Res. 2018 10 15; 24(20):4960-4967. Joseph RW, Elassaiss-Schaap J, Kefford R, Hwu WJ, Wolchok JD, Joshua AM, Ribas A, Hodi FS, Hamid O, Robert C, Daud A, Dronca R, Hersey P, Weber JS, Patnaik A, de Alwis DP, Perrone A, Zhang J, Kang SP, Ebbinghaus S, Anderson KM, Gangadhar TC. PMID: 29685882.
      View in: PubMed   Mentions: 33     Fields:    
    72. Antigen Presentation Keeps Trending in Immunotherapy Resistance. Clin Cancer Res. 2018 07 15; 24(14):3239-3241. Kalbasi A, Ribas A. PMID: 29674509.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    73. Multi-stage Differentiation Defines Melanoma Subtypes with Differential Vulnerability to Drug-Induced Iron-Dependent Oxidative Stress. Cancer Cell. 2018 05 14; 33(5):890-904.e5. Tsoi J, Robert L, Paraiso K, Galvan C, Sheu KM, Lay J, Wong DJL, Atefi M, Shirazi R, Wang X, Braas D, Grasso CS, Palaskas N, Ribas A, Graeber TG. PMID: 29657129.
      View in: PubMed   Mentions: 55     Fields:    Translation:HumansCells
    74. Cancer immunotherapy using checkpoint blockade. Science. 2018 03 23; 359(6382):1350-1355. Ribas A, Wolchok JD. PMID: 29567705.
      View in: PubMed   Mentions: 563     Fields:    Translation:Humans
    75. Genetic Mechanisms of Immune Evasion in Colorectal Cancer. Cancer Discov. 2018 06; 8(6):730-749. Grasso CS, Giannakis M, Wells DK, Hamada T, Mu XJ, Quist M, Nowak JA, Nishihara R, Qian ZR, Inamura K, Morikawa T, Nosho K, Abril-Rodriguez G, Connolly C, Escuin-Ordinas H, Geybels MS, Grady WM, Hsu L, Hu-Lieskovan S, Huyghe JR, Kim YJ, Krystofinski P, Leiserson MDM, Montoya DJ, Nadel BB, Pellegrini M, Pritchard CC, Puig-Saus C, Quist EH, Raphael BJ, Salipante SJ, Shin DS, Shinbrot E, Shirts B, Shukla S, Stanford JL, Sun W, Tsoi J, Upfill-Brown A, Wheeler DA, Wu CJ, Yu M, Zaidi SH, Zaretsky JM, Gabriel SB, Lander ES, Garraway LA, Hudson TJ, Fuchs CS, Ribas A, Ogino S, Peters U. PMID: 29510987.
      View in: PubMed   Mentions: 67     Fields:    Translation:HumansCells
    76. Selective targeting of engineered T cells using orthogonal IL-2 cytokine-receptor complexes. Science. 2018 03 02; 359(6379):1037-1042. Sockolosky JT, Trotta E, Parisi G, Picton L, Su LL, Le AC, Chhabra A, Silveria SL, George BM, King IC, Tiffany MR, Jude K, Sibener LV, Baker D, Shizuru JA, Ribas A, Bluestone JA, Garcia KC. PMID: 29496879.
      View in: PubMed   Mentions: 41     Fields:    Translation:HumansAnimalsCells
    77. Development of MK-8353, an orally administered ERK1/2 inhibitor, in patients with advanced solid tumors. JCI Insight. 2018 02 22; 3(4). PMID: 29467321.
      View in: PubMed   Mentions: 12     Fields:    Translation:HumansAnimalsCellsCTClinical Trials
    78. Health-related quality of life impact of cobimetinib in combination with vemurafenib in patients with advanced or metastatic BRAFV600 mutation-positive melanoma. Br J Cancer. 2018 03 20; 118(6):777-784. Dréno B, Ascierto PA, Atkinson V, Liszkay G, Maio M, Mandalà M, Demidov L, Stroyakovskiy D, Thomas L, de la Cruz-Merino L, Dutriaux C, Garbe C, Bartley K, Karagiannis T, Chang I, Rooney I, Koralek DO, Larkin J, McArthur GA, Ribas A. PMID: 29438370.
      View in: PubMed   Mentions: 3     Fields:    Translation:HumansCTClinical Trials
    79. Association of body-mass index and outcomes in patients with metastatic melanoma treated with targeted therapy, immunotherapy, or chemotherapy: a retrospective, multicohort analysis. Lancet Oncol. 2018 03; 19(3):310-322. PMID: 29449192.
      View in: PubMed   Mentions: 81     Fields:    Translation:Humans
    80. A kinetic investigation of interacting, stimulated T cells identifies conditions for rapid functional enhancement, minimal phenotype differentiation, and improved adoptive cell transfer tumor eradication. PLoS One. 2018; 13(1):e0191634. PMID: 29360859.
      View in: PubMed   Mentions: 3     Fields:    Translation:HumansAnimalsCells
    81. Pembrolizumab Plus Pegylated Interferon alfa-2b or Ipilimumab for Advanced Melanoma or Renal Cell Carcinoma: Dose-Finding Results from the Phase Ib KEYNOTE-029 Study. Clin Cancer Res. 2018 04 15; 24(8):1805-1815. Atkins MB, Hodi FS, Thompson JA, McDermott DF, Hwu WJ, Lawrence DP, Dawson NA, Wong DJ, Bhatia S, James M, Jain L, Robey S, Shu X, Homet Moreno B, Perini RF, Choueiri TK, Ribas A. PMID: 29358500.
      View in: PubMed   Mentions: 10     Fields:    Translation:HumansCTClinical Trials
    82. LXR/ApoE Activation Restricts Innate Immune Suppression in Cancer. Cell. 2018 02 08; 172(4):825-840.e18. Tavazoie MF, Pollack I, Tanqueco R, Ostendorf BN, Reis BS, Gonsalves FC, Kurth I, Andreu-Agullo C, Derbyshire ML, Posada J, Takeda S, Tafreshian KN, Rowinsky E, Szarek M, Waltzman RJ, Mcmillan EA, Zhao C, Mita M, Mita A, Chmielowski B, Postow MA, Ribas A, Mucida D, Tavazoie SF. PMID: 29336888.
      View in: PubMed   Mentions: 39     Fields:    Translation:AnimalsCells
    83. High response rate to PD-1 blockade in desmoplastic melanomas. Nature. 2018 01 18; 553(7688):347-350. PMID: 29320474.
      View in: PubMed   Mentions: 51     Fields:    Translation:HumansCells
    84. Mechanisms of Resistance to PD-1 and PD-L1 Blockade. Cancer J. 2018 Jan/Feb; 24(1):47-53. Nowicki TS, Hu-Lieskovan S, Ribas A. PMID: 29360728.
      View in: PubMed   Mentions: 33     Fields:    Translation:HumansAnimals
    85. Durable Complete Response After Discontinuation of Pembrolizumab in Patients With Metastatic Melanoma. J Clin Oncol. 2018 06 10; 36(17):1668-1674. PMID: 29283791.
      View in: PubMed   Mentions: 59     Fields:    Translation:HumansCTClinical Trials
    86. First-in-Class ERK1/2 Inhibitor Ulixertinib (BVD-523) in Patients with MAPK Mutant Advanced Solid Tumors: Results of a Phase I Dose-Escalation and Expansion Study. Cancer Discov. 2018 02; 8(2):184-195. Sullivan RJ, Infante JR, Janku F, Wong DJL, Sosman JA, Keedy V, Patel MR, Shapiro GI, Mier JW, Tolcher AW, Wang-Gillam A, Sznol M, Flaherty K, Buchbinder E, Carvajal RD, Varghese AM, Lacouture ME, Ribas A, Patel SP, DeCrescenzo GA, Emery CM, Groover AL, Saha S, Varterasian M, Welsch DJ, Hyman DM, Li BT. PMID: 29247021.
      View in: PubMed   Mentions: 51     Fields:    Translation:HumansCTClinical Trials
    87. Single-cell analysis resolves the cell state transition and signaling dynamics associated with melanoma drug-induced resistance. Proc Natl Acad Sci U S A. 2017 12 26; 114(52):13679-13684. Su Y, Wei W, Robert L, Xue M, Tsoi J, Garcia-Diaz A, Homet Moreno B, Kim J, Ng RH, Lee JW, Koya RC, Comin-Anduix B, Graeber TG, Ribas A, Heath JR. PMID: 29229836.
      View in: PubMed   Mentions: 27     Fields:    Translation:HumansCells
    88. Association of programmed death ligand-1 (PD-L1) expression with treatment outcomes in patients with BRAF mutation-positive melanoma treated with vemurafenib or cobimetinib combined with vemurafenib. Pigment Cell Melanoma Res. 2018 07; 31(4):516-522. PMID: 29156488.
      View in: PubMed   Mentions:    Fields:    Translation:HumansCTClinical Trials
    89. Vemurafenib treatment for patients with locally advanced, unresectable stage IIIC or metastatic melanoma and activating exon 15 BRAF mutations other than V600E. Melanoma Res. 2017 12; 27(6):585-590. Hallmeyer S, Gonzalez R, Lawson DH, Cranmer LD, Linette GP, Puzanov I, Taback B, Cowey CL, Ribas A, Daniels GA, Moore T, Gibney GT, Tawbi H, Whitman E, Lee G, Mun Y, Liu S, Hamid O. PMID: 29076950.
      View in: PubMed   Mentions: 3     Fields:    Translation:HumansCTClinical Trials
    90. Final analysis of a randomised trial comparing pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory advanced melanoma. Eur J Cancer. 2017 11; 86:37-45. PMID: 28961465.
      View in: PubMed   Mentions: 35     Fields:    Translation:HumansCTClinical Trials
    91. Axicabtagene ciloleucel, a first-in-class CAR T cell therapy for aggressive NHL. Leuk Lymphoma. 2018 08; 59(8):1785-1796. PMID: 29058502.
      View in: PubMed   Mentions: 28     Fields:    Translation:HumansCells
    92. High frequency of brain metastases after adjuvant therapy for high-risk melanoma. Cancer Med. 2017 Nov; 6(11):2576-2585. PMID: 28994212.
      View in: PubMed   Mentions: 5     Fields:    Translation:Humans
    93. Endocrinopathies with use of cancer immunotherapies. Clin Endocrinol (Oxf). 2018 02; 88(2):327-332. PMID: 28941311.
      View in: PubMed   Mentions: 4     Fields:    Translation:Humans
    94. Oncolytic Virotherapy Promotes Intratumoral T Cell Infiltration and Improves Anti-PD-1 Immunotherapy. Cell. 2017 Sep 07; 170(6):1109-1119.e10. Ribas A, Dummer R, Puzanov I, VanderWalde A, Andtbacka RHI, Michielin O, Olszanski AJ, Malvehy J, Cebon J, Fernandez E, Kirkwood JM, Gajewski TF, Chen L, Gorski KS, Anderson AA, Diede SJ, Lassman ME, Gansert J, Hodi FS, Long GV. PMID: 28886381.
      View in: PubMed   Mentions: 220     Fields:    Translation:HumansCellsCTClinical Trials
    95. Recurrent Tumor Cell-Intrinsic and -Extrinsic Alterations during MAPKi-Induced Melanoma Regression and Early Adaptation. Cancer Discov. 2017 11; 7(11):1248-1265. PMID: 28864476.
      View in: PubMed   Mentions: 29     Fields:    Translation:HumansAnimalsCells
    96. Survival of patients with advanced metastatic melanoma: the impact of novel therapies-update 2017. Eur J Cancer. 2017 09; 83:247-257. PMID: 28756137.
      View in: PubMed   Mentions: 54     Fields:    Translation:Humans
    97. Pembrolizumab versus ipilimumab for advanced melanoma: final overall survival results of a multicentre, randomised, open-label phase 3 study (KEYNOTE-006). Lancet. 2017 Oct 21; 390(10105):1853-1862. Schachter J, Ribas A, Long GV, Arance A, Grob JJ, Mortier L, Daud A, Carlino MS, McNeil C, Lotem M, Larkin J, Lorigan P, Neyns B, Blank C, Petrella TM, Hamid O, Zhou H, Ebbinghaus S, Ibrahim N, Robert C. PMID: 28822576.
      View in: PubMed   Mentions: 189     Fields:    Translation:HumansCTClinical Trials
    98. ATR inhibition facilitates targeting of leukemia dependence on convergent nucleotide biosynthetic pathways. Nat Commun. 2017 08 14; 8(1):241. PMID: 28808226.
      View in: PubMed   Mentions: 11     Fields:    Translation:HumansAnimalsCells
    99. Collaborative Care in Melanoma: The Essential Role of the Nurse?. Clin J Oncol Nurs. 2017 08 01; 21(4 Suppl):4-6. Kirkwood JM, Ribas A. PMID: 28738052.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    100. Standard-dose pembrolizumab in combination with reduced-dose ipilimumab for patients with advanced melanoma (KEYNOTE-029): an open-label, phase 1b trial. Lancet Oncol. 2017 09; 18(9):1202-1210. Long GV, Atkinson V, Cebon JS, Jameson MB, Fitzharris BM, McNeil CM, Hill AG, Ribas A, Atkins MB, Thompson JA, Hwu WJ, Hodi FS, Menzies AM, Guminski AD, Kefford R, Kong BY, Tamjid B, Srivastava A, Lomax AJ, Islam M, Shu X, Ebbinghaus S, Ibrahim N, Carlino MS. PMID: 28729151.
      View in: PubMed   Mentions: 50     Fields:    Translation:HumansCTClinical Trials
    101. IFN-?-related mRNA profile predicts clinical response to PD-1 blockade. J Clin Invest. 2017 Aug 01; 127(8):2930-2940. Ayers M, Lunceford J, Nebozhyn M, Murphy E, Loboda A, Kaufman DR, Albright A, Cheng JD, Kang SP, Shankaran V, Piha-Paul SA, Yearley J, Seiwert TY, Ribas A, McClanahan TK. PMID: 28650338.
      View in: PubMed   Mentions: 361     Fields:    Translation:HumansCellsCTClinical Trials
    102. MAPK Signaling and Inflammation Link Melanoma Phenotype Switching to Induction of CD73 during Immunotherapy. Cancer Res. 2017 09 01; 77(17):4697-4709. Reinhardt J, Landsberg J, Schmid-Burgk JL, Ramis BB, Bald T, Glodde N, Lopez-Ramos D, Young A, Ngiow SF, Nettersheim D, Schorle H, Quast T, Kolanus W, Schadendorf D, Long GV, Madore J, Scolyer RA, Ribas A, Smyth MJ, Tumeh PC, Tüting T, Hölzel M. PMID: 28652246.
      View in: PubMed   Mentions: 23     Fields:    Translation:HumansAnimalsCells
    103. Clinical features of serous retinopathy observed with cobimetinib in patients with BRAF-mutated melanoma treated in the randomized coBRIM study. J Transl Med. 2017 06 24; 15(1):146. de la Cruz-Merino L, Di Guardo L, Grob JJ, Venosa A, Larkin J, McArthur GA, Ribas A, Ascierto PA, Evans JTR, Gomez-Escobar A, Barteselli G, Eng S, Hsu JJ, Uyei A, Dréno B. PMID: 28646893.
      View in: PubMed   Mentions: 7     Fields:    Translation:Humans
    104. Three-year pooled analysis of factors associated with clinical outcomes across dabrafenib and trametinib combination therapy phase 3 randomised trials. Eur J Cancer. 2017 09; 82:45-55. PMID: 28648698.
      View in: PubMed   Mentions: 34     Fields:    Translation:HumansCTClinical Trials
    105. SnapShot: Immune Checkpoint Inhibitors. Cancer Cell. 2017 06 12; 31(6):848-848.e1. Abril-Rodriguez G, Ribas A. PMID: 28609660.
      View in: PubMed   Mentions: 33     Fields:    Translation:Humans
    106. Gene Expression Profiling in BRAF-Mutated Melanoma Reveals Patient Subgroups with Poor Outcomes to Vemurafenib That May Be Overcome by Cobimetinib Plus Vemurafenib. Clin Cancer Res. 2017 Sep 01; 23(17):5238-5245. PMID: 28536307.
      View in: PubMed   Mentions: 12     Fields:    Translation:Humans
    107. Interferon Receptor Signaling Pathways Regulating PD-L1 and PD-L2 Expression. Cell Rep. 2017 05 09; 19(6):1189-1201. PMID: 28494868.
      View in: PubMed   Mentions: 226     Fields:    Translation:HumansCells
    108. Targeted agents and immunotherapies: optimizing outcomes in melanoma. Nat Rev Clin Oncol. 2017 Aug; 14(8):463-482. PMID: 28374786.
      View in: PubMed   Mentions: 196     Fields:    Translation:Humans
    109. MAPK pathway inhibition induces MET and GAB1 levels, priming BRAF mutant melanoma for rescue by hepatocyte growth factor. Oncotarget. 2017 Mar 14; 8(11):17795-17809. PMID: 28147313.
      View in: PubMed   Mentions: 10     Fields:    Translation:HumansAnimalsCells
    110. Preparation of peptide-MHC and T-cell receptor dextramers by biotinylated dextran doping. Biotechniques. 2017 03 01; 62(3):123-130. PMID: 28298179.
      View in: PubMed   Mentions: 4     Fields:    Translation:HumansCells
    111. Primary, Adaptive, and Acquired Resistance to Cancer Immunotherapy. Cell. 2017 02 09; 168(4):707-723. PMID: 28187290.
      View in: PubMed   Mentions: 628     Fields:    Translation:HumansAnimalsCells
    112. Genomic and Transcriptomic Features of Response to Anti-PD-1 Therapy in Metastatic Melanoma. Cell. 2017 01 26; 168(3):542. PMID: 28129544.
      View in: PubMed   Mentions: 45     Fields:    
    113. New Combination Strategies Using Programmed Cell Death 1/Programmed Cell Death Ligand 1 Checkpoint Inhibitors as a Backbone. Cancer J. 2017 Jan/Feb; 23(1):10-22. PMID: 28114250.
      View in: PubMed   Mentions: 13     Fields:    Translation:HumansAnimals
    114. Infiltration of CD8 T Cells and Expression of PD-1 and PD-L1 in Synovial Sarcoma. Cancer Immunol Res. 2017 02; 5(2):118-126. PMID: 28039162.
      View in: PubMed   Mentions: 14     Fields:    Translation:HumansCells
    115. Primary Resistance to PD-1 Blockade Mediated by JAK1/2 Mutations. Cancer Discov. 2017 02; 7(2):188-201. PMID: 27903500.
      View in: PubMed   Mentions: 229     Fields:    Translation:HumansCells
    116. What does PD-L1 positive or negative mean? J Exp Med. 2016 12 12; 213(13):2835-2840. PMID: 27903604.
      View in: PubMed   Mentions: 62     Fields:    Translation:HumansAnimalsCells
    117. Factors predictive of response, disease progression, and overall survival after dabrafenib and trametinib combination treatment: a pooled analysis of individual patient data from randomised trials. Lancet Oncol. 2016 Dec; 17(12):1743-1754. PMID: 27864013.
      View in: PubMed   Mentions: 60     Fields:    Translation:Humans
    118. Programmed Death-Ligand 1 Expression and Response to the Anti-Programmed Death 1 Antibody Pembrolizumab in Melanoma. J Clin Oncol. 2016 12; 34(34):4102-4109. PMID: 27863197.
      View in: PubMed   Mentions: 131     Fields:    Translation:HumansCTClinical Trials
    119. Cancer Research in the 21st Century. Ann Surg. 2016 10; 264(4):555-65. PMID: 27537535.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    120. A phase I dose-escalation study of TAK-733, an investigational oral MEK inhibitor, in patients with advanced solid tumors. Invest New Drugs. 2017 02; 35(1):47-58. PMID: 27650277.
      View in: PubMed   Mentions: 7     Fields:    Translation:HumansCellsCTClinical Trials
    121. JUN dependency in distinct early and late BRAF inhibition adaptation states of melanoma. Cell Discov. 2016; 2:16028. PMID: 27648299.
      View in: PubMed   Mentions:
    122. Response to Programmed Cell Death-1 Blockade in a Murine Melanoma Syngeneic Model Requires Costimulation, CD4, and CD8 T Cells. Cancer Immunol Res. 2016 10; 4(10):845-857. PMID: 27589875.
      View in: PubMed   Mentions: 32     Fields:    Translation:AnimalsCells
    123. Health-related quality of life in the randomised KEYNOTE-002 study of pembrolizumab versus chemotherapy in patients with ipilimumab-refractory melanoma. Eur J Cancer. 2016 11; 67:46-54. PMID: 27596353.
      View in: PubMed   Mentions: 15     Fields:    Translation:HumansCTClinical Trials
    124. The efficacy of anti-PD-1 agents in acral and mucosal melanoma. Cancer. 2016 Nov 15; 122(21):3354-3362. PMID: 27533633.
      View in: PubMed   Mentions: 56     Fields:    Translation:Humans
    125. Cutaneous wound healing through paradoxical MAPK activation by BRAF inhibitors. Nat Commun. 2016 08 01; 7:12348. PMID: 27476449.
      View in: PubMed   Mentions: 10     Fields:    Translation:HumansAnimalsCells
    126. Cobimetinib combined with vemurafenib in advanced BRAF(V600)-mutant melanoma (coBRIM): updated efficacy results from a randomised, double-blind, phase 3 trial. Lancet Oncol. 2016 Sep; 17(9):1248-60. PMID: 27480103.
      View in: PubMed   Mentions: 146     Fields:    Translation:HumansCTClinical Trials
    127. Mutations Associated with Acquired Resistance to PD-1 Blockade in Melanoma. N Engl J Med. 2016 Sep 01; 375(9):819-29. PMID: 27433843.
      View in: PubMed   Mentions: 595     Fields:    Translation:HumansCells
    128. Corrigendum: sFRP2 in the aged microenvironment drives melanoma metastasis and therapy resistance. Nature. 2016 Sep 08; 537(7619):254. PMID: 27383789.
      View in: PubMed   Mentions: 4     Fields:    
    129. CRAF R391W is a melanoma driver oncogene. Sci Rep. 2016 06 08; 6:27454. PMID: 27273450.
      View in: PubMed   Mentions: 3     Fields:    Translation:HumansAnimalsCells
    130. CANCER IMMUNOLOGY. The "cancer immunogram". Science. 2016 May 06; 352(6286):658-60. PMID: 27151852.
      View in: PubMed   Mentions: 163     Fields:    Translation:HumansAnimalsCells
    131. Association of Pembrolizumab With Tumor Response and Survival Among Patients With Advanced Melanoma. JAMA. 2016 Apr 19; 315(15):1600-9. PMID: 27092830.
      View in: PubMed   Mentions: 254     Fields:    Translation:HumansCTClinical Trials
    132. The state of melanoma: challenges and opportunities. Pigment Cell Melanoma Res. 2016 07; 29(4):404-16. PMID: 27087480.
      View in: PubMed   Mentions: 20     Fields:    Translation:HumansCells
    133. sFRP2 in the aged microenvironment drives melanoma metastasis and therapy resistance. Nature. 2016 Apr 14; 532(7598):250-4. PMID: 27042933.
      View in: PubMed   Mentions: 74     Fields:    Translation:HumansAnimalsCells
    134. Genomic and Transcriptomic Features of Response to Anti-PD-1 Therapy in Metastatic Melanoma. Cell. 2016 Mar 24; 165(1):35-44. PMID: 26997480.
      View in: PubMed   Mentions: 530     Fields:    Translation:HumansCells
    135. Immunodynamics: a cancer immunotherapy trials network review of immune monitoring in immuno-oncology clinical trials. J Immunother Cancer. 2016; 4:15. PMID: 26981245.
      View in: PubMed   Mentions: 19     Fields:    
    136. Evaluation of Immune-Related Response Criteria and RECIST v1.1 in Patients With Advanced Melanoma Treated With Pembrolizumab. J Clin Oncol. 2016 05 01; 34(13):1510-7. PMID: 26951310.
      View in: PubMed   Mentions: 173     Fields:    Translation:HumansCTClinical Trials
    137. Combining targeted therapy with immunotherapy. Can 1+1 equal more than 2? Semin Immunol. 2016 02; 28(1):73-80. PMID: 26861544.
      View in: PubMed   Mentions: 12     Fields:    Translation:HumansCells
    138. PD-1 Blockade Expands Intratumoral Memory T Cells. Cancer Immunol Res. 2016 Mar; 4(3):194-203. PMID: 26787823.
      View in: PubMed   Mentions: 93     Fields:    Translation:HumansCellsCTClinical Trials
    139. Targeted Therapy for Melanoma. Cancer Treat Res. 2016; 167:251-62. PMID: 26601866.
      View in: PubMed   Mentions: 31     Fields:    Translation:Humans
    140. Survival of patients with advanced metastatic melanoma: The impact of novel therapies. Eur J Cancer. 2016 Jan; 53:125-34. PMID: 26707829.
      View in: PubMed   Mentions: 48     Fields:    Translation:Humans
    141. Host immunity contributes to the anti-melanoma activity of BRAF inhibitors. J Clin Invest. 2016 Jan; 126(1):402-3. PMID: 26595810.
      View in: PubMed   Mentions: 4     Fields:    
    142. Acquired BRAF inhibitor resistance: A multicenter meta-analysis of the spectrum and frequencies, clinical behaviour, and phenotypic associations of resistance mechanisms. Eur J Cancer. 2015 Dec; 51(18):2792-9. PMID: 26608120.
      View in: PubMed   Mentions: 71     Fields:    Translation:HumansCells
    143. An Effective Immuno-PET Imaging Method to Monitor CD8-Dependent Responses to Immunotherapy. Cancer Res. 2016 Jan 01; 76(1):73-82. PMID: 26573799.
      View in: PubMed   Mentions: 66     Fields:    Translation:HumansAnimalsCells
    144. Comparison of dabrafenib and trametinib combination therapy with vemurafenib monotherapy on health-related quality of life in patients with unresectable or metastatic cutaneous BRAF Val600-mutation-positive melanoma (COMBI-v): results of a phase 3, open-label, randomised trial. Lancet Oncol. 2015 Oct; 16(13):1389-98. PMID: 26433819.
      View in: PubMed   Mentions: 41     Fields:    Translation:HumansCTClinical Trials
    145. Combination of antibodies directed against different ErbB3 surface epitopes prevents the establishment of resistance to BRAF/MEK inhibitors in melanoma. Oncotarget. 2015 Sep 22; 6(28):24823-41. PMID: 26208478.
      View in: PubMed   Mentions: 19     Fields:    Translation:HumansAnimalsCells
    146. Non-genomic and Immune Evolution of Melanoma Acquiring MAPKi Resistance. Cell. 2015 Sep 10; 162(6):1271-85. PMID: 26359985.
      View in: PubMed   Mentions: 150     Fields:    Translation:HumansCells
    147. Long term survival with cytotoxic T lymphocyte-associated antigen 4 blockade using tremelimumab. Eur J Cancer. 2015 Nov; 51(17):2689-97. PMID: 26364516.
      View in: PubMed   Mentions: 20     Fields:    Translation:Humans
    148. Releasing the Brakes on Cancer Immunotherapy. N Engl J Med. 2015 Oct 15; 373(16):1490-2. PMID: 26348216.
      View in: PubMed   Mentions: 48     Fields:    Translation:HumansAnimalsCells
    149. Combined treatment with dabrafenib and trametinib with immune-stimulating antibodies for BRAF mutant melanoma. Oncoimmunology. 2016 Jul; 5(7):e1052212. PMID: 27622011.
      View in: PubMed   Mentions:
    150. Adaptive Immune Resistance: How Cancer Protects from Immune Attack. Cancer Discov. 2015 Sep; 5(9):915-9. PMID: 26272491.
      View in: PubMed   Mentions: 135     Fields:    Translation:HumansAnimalsCells
    151. Erratum to: Antitumor activity of the ERK inhibitor SCH722984 against BRAF mutant, NRAS mutant and wild-type melanoma. Mol Cancer. 2015 Jul 02; 14:128. PMID: 26134498.
      View in: PubMed   Mentions: 2     Fields:    
    152. Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial. Lancet Oncol. 2015 Aug; 16(8):908-18. PMID: 26115796.
      View in: PubMed   Mentions: 401     Fields:    Translation:HumansCTClinical Trials
    153. Excluding T Cells: Is ß-Catenin the Full Story? Cancer Cell. 2015 Jun 08; 27(6):749-50. PMID: 26058073.
      View in: PubMed   Mentions: 5     Fields:    Translation:HumansAnimalsCells
    154. Classifying Cancers Based on T-cell Infiltration and PD-L1. Cancer Res. 2015 Jun 01; 75(11):2139-45. PMID: 25977340.
      View in: PubMed   Mentions: 332     Fields:    Translation:HumansCells
    155. Dabrafenib and trametinib versus dabrafenib and placebo for Val600 BRAF-mutant melanoma: a multicentre, double-blind, phase 3 randomised controlled trial. Lancet. 2015 Aug 01; 386(9992):444-51. PMID: 26037941.
      View in: PubMed   Mentions: 275     Fields:    Translation:HumansCTClinical Trials
    156. Long-term outcome in BRAF(V600E) melanoma patients treated with vemurafenib: Patterns of disease progression and clinical management of limited progression. Eur J Cancer. 2015 Jul; 51(11):1435-43. PMID: 25980594.
      View in: PubMed   Mentions: 29     Fields:    Translation:HumansCTClinical Trials
    157. Inhibition of colony stimulating factor-1 receptor improves antitumor efficacy of BRAF inhibition. BMC Cancer. 2015 May 05; 15:356. PMID: 25939769.
      View in: PubMed   Mentions: 21     Fields:    Translation:AnimalsCells
    158. Melanoma. Nat Rev Dis Primers. 2015 04 23; 1:15003. PMID: 27188223.
      View in: PubMed   Mentions: 84     Fields:    Translation:HumansCells
    159. Pembrolizumab versus Ipilimumab in Advanced Melanoma. N Engl J Med. 2015 Jun 25; 372(26):2521-32. PMID: 25891173.
      View in: PubMed   Mentions: 1294     Fields:    Translation:HumansCTClinical Trials
    160. Improved antitumor activity of immunotherapy with BRAF and MEK inhibitors in BRAF(V600E) melanoma. Sci Transl Med. 2015 Mar 18; 7(279):279ra41. PMID: 25787767.
      View in: PubMed   Mentions: 145     Fields:    Translation:HumansAnimalsCells
    161. Health-related quality of life impact in a randomised phase III study of the combination of dabrafenib and trametinib versus dabrafenib monotherapy in patients with BRAF V600 metastatic melanoma. Eur J Cancer. 2015 May; 51(7):833-40. PMID: 25794603.
      View in: PubMed   Mentions: 24     Fields:    Translation:HumansCTClinical Trials
    162. Erratum: anticancer immunotherapy by CTLA-4 blockade: obligatory contribution of IL-2 receptors and negative prognostic impact of soluble CD25. Cell Res. 2015 Mar; 25(3):399-400. PMID: 25732764.
      View in: PubMed   Mentions: 2     Fields:    
    163. Consensus nomenclature for CD8+ T cell phenotypes in cancer. Oncoimmunology. 2015 Apr; 4(4):e998538. PMID: 26137416.
      View in: PubMed   Mentions:
    164. Anti-PD-1 therapy in melanoma. Semin Oncol. 2015 Jun; 42(3):466-73. PMID: 25965365.
      View in: PubMed   Mentions: 19     Fields:    Translation:HumansAnimals
    165. Gauging the Long-Term Benefits of Ipilimumab in Melanoma. J Clin Oncol. 2015 Jun 10; 33(17):1865-6. PMID: 25667273.
      View in: PubMed   Mentions: 11     Fields:    Translation:Humans
    166. Combination of pan-RAF and MEK inhibitors in NRAS mutant melanoma. Mol Cancer. 2015 Feb 03; 14:27. PMID: 25645078.
      View in: PubMed   Mentions: 19     Fields:    Translation:HumansCells
    167. The evolution of checkpoint blockade as a cancer therapy: what's here, what's next? Curr Opin Immunol. 2015 Apr; 33:23-35. PMID: 25621841.
      View in: PubMed   Mentions: 106     Fields:    Translation:HumansAnimalsCells
    168. Tunable-combinatorial mechanisms of acquired resistance limit the efficacy of BRAF/MEK cotargeting but result in melanoma drug addiction. Cancer Cell. 2015 Feb 09; 27(2):240-56. PMID: 25600339.
      View in: PubMed   Mentions: 90     Fields:    Translation:HumansCells
    169. Anticancer immunotherapy by CTLA-4 blockade: obligatory contribution of IL-2 receptors and negative prognostic impact of soluble CD25. Cell Res. 2015 Feb; 25(2):208-24. PMID: 25582080.
      View in: PubMed   Mentions: 60     Fields:    Translation:HumansAnimalsCells
    170. Low MITF/AXL ratio predicts early resistance to multiple targeted drugs in melanoma. Nat Commun. 2014 Dec 15; 5:5712. PMID: 25502142.
      View in: PubMed   Mentions: 152     Fields:    Translation:HumansAnimalsCells
    171. PD-1 blockade induces responses by inhibiting adaptive immune resistance. Nature. 2014 Nov 27; 515(7528):568-71. PMID: 25428505.
      View in: PubMed   Mentions: 1554     Fields:    Translation:HumansCellsCTClinical Trials
    172. Genetic basis for clinical response to CTLA-4 blockade in melanoma. N Engl J Med. 2014 Dec 04; 371(23):2189-2199. PMID: 25409260.
      View in: PubMed   Mentions: 1199     Fields:    Translation:Humans
    173. Improved overall survival in melanoma with combined dabrafenib and trametinib. N Engl J Med. 2015 Jan 01; 372(1):30-9. PMID: 25399551.
      View in: PubMed   Mentions: 594     Fields:    Translation:HumansCTClinical Trials
    174. Future perspectives in melanoma research: meeting report from the "Melanoma Bridge", Napoli, December 5th-8th 2013. J Transl Med. 2014 Oct 28; 12:277. PMID: 25348889.
      View in: PubMed   Mentions: 8     Fields:    Translation:Humans
    175. Southwest Oncology Group S0008: a phase III trial of high-dose interferon Alfa-2b versus cisplatin, vinblastine, and dacarbazine, plus interleukin-2 and interferon in patients with high-risk melanoma--an intergroup study of cancer and leukemia Group B, Children's Oncology Group, Eastern Cooperative Oncology Group, and Southwest Oncology Group. J Clin Oncol. 2014 Nov 20; 32(33):3771-8. PMID: 25332243.
      View in: PubMed   Mentions: 25     Fields:    Translation:HumansCTClinical Trials
    176. Combined vemurafenib and cobimetinib in BRAF-mutated melanoma. N Engl J Med. 2014 Nov 13; 371(20):1867-76. PMID: 25265494.
      View in: PubMed   Mentions: 462     Fields:    Translation:HumansCTClinical Trials
    177. Combined BRAF and MEK inhibition versus BRAF inhibition alone in melanoma. N Engl J Med. 2014 Nov 13; 371(20):1877-88. PMID: 25265492.
      View in: PubMed   Mentions: 437     Fields:    Translation:HumansCTClinical Trials
    178. Phase 2 study of RO4929097, a gamma-secretase inhibitor, in metastatic melanoma: SWOG 0933. Cancer. 2015 Feb 01; 121(3):432-440. PMID: 25250858.
      View in: PubMed   Mentions: 28     Fields:    Translation:HumansCellsCTClinical Trials
    179. T-cell immunotherapy: looking forward. Mol Ther. 2014 Sep; 22(9):1564-74. PMID: 25186558.
      View in: PubMed   Mentions: 24     Fields:    Translation:HumansCells
    180. Antitumor activity of the ERK inhibitor SCH772984 [corrected] against BRAF mutant, NRAS mutant and wild-type melanoma. Mol Cancer. 2014 Aug 20; 13:194. PMID: 25142146.
      View in: PubMed   Mentions: 31     Fields:    Translation:HumansCells
    181. Bilateral subfoveal neurosensory retinal detachment associated with MEK inhibitor use for metastatic cancer. JAMA Ophthalmol. 2014 Aug; 132(8):1005-9. PMID: 24852144.
      View in: PubMed   Mentions: 16     Fields:    Translation:Humans
    182. Correlating animal and human phase Ia/Ib clinical data with CALAA-01, a targeted, polymer-based nanoparticle containing siRNA. Proc Natl Acad Sci U S A. 2014 Aug 05; 111(31):11449-54. PMID: 25049380.
      View in: PubMed   Mentions: 64     Fields:    Translation:HumansAnimalsPHPublic HealthCTClinical Trials
    183. HSV-sr39TK positron emission tomography and suicide gene elimination of human hematopoietic stem cells and their progeny in humanized mice. Cancer Res. 2014 Sep 15; 74(18):5173-83. PMID: 25038231.
      View in: PubMed   Mentions: 13     Fields:    Translation:HumansAnimalsCells
    184. Combination of vemurafenib and cobimetinib in patients with advanced BRAF(V600)-mutated melanoma: a phase 1b study. Lancet Oncol. 2014 Aug; 15(9):954-65. PMID: 25037139.
      View in: PubMed   Mentions: 74     Fields:    Translation:HumansCTClinical Trials
    185. Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial. Lancet. 2014 Sep 20; 384(9948):1109-17. PMID: 25034862.
      View in: PubMed   Mentions: 536     Fields:    Translation:HumansCTClinical Trials
    186. Adjuvant vaccine immunotherapy of resected, clinically node-negative melanoma: long-term outcome and impact of HLA class I antigen expression on overall survival. Cancer Immunol Res. 2014 Oct; 2(10):981-7. PMID: 24994597.
      View in: PubMed   Mentions: 1     Fields:    Translation:HumansCTClinical Trials
    187. The future of cancer therapy: selecting patients likely to respond to PD1/L1 blockade. Clin Cancer Res. 2014 Oct 01; 20(19):4982-4. PMID: 24970841.
      View in: PubMed   Mentions: 37     Fields:    Translation:Humans
    188. Distinct immunological mechanisms of CTLA-4 and PD-1 blockade revealed by analyzing TCR usage in blood lymphocytes. Oncoimmunology. 2014; 3:e29244. PMID: 25083336.
      View in: PubMed   Mentions:
    189. Combining targeted therapy with immunotherapy in BRAF-mutant melanoma: promise and challenges. J Clin Oncol. 2014 Jul 20; 32(21):2248-54. PMID: 24958825.
      View in: PubMed   Mentions: 68     Fields:    Translation:Humans
    190. Improved survival with T cell clonotype stability after anti-CTLA-4 treatment in cancer patients. Sci Transl Med. 2014 May 28; 6(238):238ra70. PMID: 24871131.
      View in: PubMed   Mentions: 135     Fields:    Translation:Humans
    191. Effects of MAPK and PI3K pathways on PD-L1 expression in melanoma. Clin Cancer Res. 2014 Jul 01; 20(13):3446-57. PMID: 24812408.
      View in: PubMed   Mentions: 120     Fields:    Translation:HumansCells
    192. Effects of AKT inhibitor therapy in response and resistance to BRAF inhibition in melanoma. Mol Cancer. 2014 Apr 16; 13:83. PMID: 24735930.
      View in: PubMed   Mentions: 28     Fields:    Translation:HumansCells
    193. Adoptive transfer of MART-1 T-cell receptor transgenic lymphocytes and dendritic cell vaccination in patients with metastatic melanoma. Clin Cancer Res. 2014 May 01; 20(9):2457-65. PMID: 24634374.
      View in: PubMed   Mentions: 62     Fields:    Translation:HumansCellsPHPublic HealthCTClinical Trials
    194. CTLA4 blockade broadens the peripheral T-cell receptor repertoire. Clin Cancer Res. 2014 May 01; 20(9):2424-32. PMID: 24583799.
      View in: PubMed   Mentions: 100     Fields:    Translation:HumansCells
    195. Loss of NF1 in cutaneous melanoma is associated with RAS activation and MEK dependence. Cancer Res. 2014 Apr 15; 74(8):2340-50. PMID: 24576830.
      View in: PubMed   Mentions: 91     Fields:    Translation:HumansCells
    196. Safety and efficacy of vemurafenib in BRAF(V600E) and BRAF(V600K) mutation-positive melanoma (BRIM-3): extended follow-up of a phase 3, randomised, open-label study. Lancet Oncol. 2014 Mar; 15(3):323-32. PMID: 24508103.
      View in: PubMed   Mentions: 266     Fields:    Translation:HumansCTClinical Trials
    197. Exposure to a histone deacetylase inhibitor has detrimental effects on human lymphocyte viability and function. Cancer Immunol Res. 2014 May; 2(5):459-68. PMID: 24795358.
      View in: PubMed   Mentions: 9     Fields:    Translation:HumansCells
    198. Response of BRAF-mutant melanoma to BRAF inhibition is mediated by a network of transcriptional regulators of glycolysis. Cancer Discov. 2014 Apr; 4(4):423-33. PMID: 24469106.
      View in: PubMed   Mentions: 84     Fields:    Translation:HumansCells
    199. The effects of a high-fat meal on single-dose vemurafenib pharmacokinetics. J Clin Pharmacol. 2014 Apr; 54(4):368-74. PMID: 24374975.
      View in: PubMed   Mentions: 10     Fields:    Translation:Humans
    200. A single-arm, open-label, expanded access study of vemurafenib in patients with metastatic melanoma in the United States. Cancer J. 2014 Jan-Feb; 20(1):18-24. PMID: 24445759.
      View in: PubMed   Mentions: 16     Fields:    Translation:HumansCTClinical Trials
    201. Novel insights/translational implication from the emerging biology of melanoma. Methods Mol Biol. 2014; 1102:3-9. PMID: 24258970.
      View in: PubMed   Mentions: 2     Fields:    Translation:HumansCells
    202. New drug targets in metastatic melanoma. J Pathol. 2014 Jan; 232(2):134-41. PMID: 24027077.
      View in: PubMed   Mentions: 13     Fields:    Translation:HumansAnimalsCells
    203. COX-2 inhibition prevents the appearance of cutaneous squamous cell carcinomas accelerated by BRAF inhibitors. Mol Oncol. 2014 Mar; 8(2):250-60. PMID: 24345644.
      View in: PubMed   Mentions: 17     Fields:    Translation:HumansAnimals
    204. A novel AKT1 mutant amplifies an adaptive melanoma response to BRAF inhibition. Cancer Discov. 2014 Jan; 4(1):69-79. PMID: 24265152.
      View in: PubMed   Mentions: 72     Fields:    Translation:HumansCells
    205. Acquired resistance and clonal evolution in melanoma during BRAF inhibitor therapy. Cancer Discov. 2014 Jan; 4(1):80-93. PMID: 24265155.
      View in: PubMed   Mentions: 321     Fields:    Translation:HumansCells
    206. Inhibition of CSF-1 receptor improves the antitumor efficacy of adoptive cell transfer immunotherapy. Cancer Res. 2014 Jan 01; 74(1):153-161. PMID: 24247719.
      View in: PubMed   Mentions: 102     Fields:    Translation:AnimalsCells
    207. Natural killer T cells in advanced melanoma patients treated with tremelimumab. PLoS One. 2013; 8(10):e76829. PMID: 24167550.
      View in: PubMed   Mentions: 6     Fields:    Translation:HumansCellsCTClinical Trials
    208. PET imaging to non-invasively study immune activation leading to antitumor responses with a 4-1BB agonistic antibody. J Immunother Cancer. 2013; 1:14. PMID: 24829750.
      View in: PubMed   Mentions: 4     Fields:    
    209. Phase II trial (BREAK-2) of the BRAF inhibitor dabrafenib (GSK2118436) in patients with metastatic melanoma. J Clin Oncol. 2013 Sep 10; 31(26):3205-11. PMID: 23918947.
      View in: PubMed   Mentions: 129     Fields:    Translation:HumansCTClinical Trials
    210. Reply to K.S. Wilson et al. J Clin Oncol. 2013 Aug 01; 31(22):2836-7. PMID: 24058931.
      View in: PubMed   Mentions: 4     Fields:    Translation:Humans
    211. Impact of MET expression on outcome in BRAF(V600E/K) advanced melanoma. Histopathology. 2013 Sep; 63(3):351-61. PMID: 23802768.
      View in: PubMed   Mentions: 5     Fields:    Translation:HumansAnimalsCellsCTClinical Trials
    212. Future perspectives in melanoma research. Meeting report from the "Melanoma Bridge. Napoli, December 2nd-4th 2012". J Transl Med. 2013 Jun 03; 11:137. PMID: 23731854.
      View in: PubMed   Mentions: 9     Fields:    Translation:HumansAnimals
    213. Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma. N Engl J Med. 2013 Jul 11; 369(2):134-44. PMID: 23724846.
      View in: PubMed   Mentions: 1219     Fields:    Translation:HumansCTClinical Trials
    214. BRAF-targeted therapy and immune responses to melanoma. Oncoimmunology. 2013 Jun 01; 2(6):e24462. PMID: 23894707.
      View in: PubMed   Mentions:
    215. Severe liver and skin toxicity after radiation and vemurafenib in metastatic melanoma. J Clin Oncol. 2013 Jun 10; 31(17):e283-7. PMID: 23650406.
      View in: PubMed   Mentions: 21     Fields:    Translation:HumansPHPublic Health
    216. Pharmacodynamic effects and mechanisms of resistance to vemurafenib in patients with metastatic melanoma. J Clin Oncol. 2013 May 10; 31(14):1767-74. PMID: 23569304.
      View in: PubMed   Mentions: 130     Fields:    Translation:HumansCellsCTClinical Trials
    217. Hepatotoxicity with combination of vemurafenib and ipilimumab. N Engl J Med. 2013 Apr 04; 368(14):1365-6. PMID: 23550685.
      View in: PubMed   Mentions: 218     Fields:    Translation:HumansCTClinical Trials
    218. Combining cancer immunotherapy and targeted therapy. Curr Opin Immunol. 2013 Apr; 25(2):291-6. PMID: 23561594.
      View in: PubMed   Mentions: 27     Fields:    Translation:HumansCells
    219. Multifunctional T-cell analyses to study response and progression in adoptive cell transfer immunotherapy. Cancer Discov. 2013 Apr; 3(4):418-29. PMID: 23519018.
      View in: PubMed   Mentions: 43     Fields:    Translation:HumansCellsCTClinical Trials
    220. Facial palsy as a side effect of vemurafenib treatment in patients with metastatic melanoma. J Clin Oncol. 2013 Apr 20; 31(12):e215-7. PMID: 23509307.
      View in: PubMed   Mentions: 10     Fields:    Translation:Humans
    221. Polymer nanofiber-embedded microchips for detection, isolation, and molecular analysis of single circulating melanoma cells. Angew Chem Int Ed Engl. 2013 Mar 18; 52(12):3379-83. PMID: 23436302.
      View in: PubMed   Mentions: 50     Fields:    Translation:HumansCells
    222. Allelic exclusion and peripheral reconstitution by TCR transgenic T cells arising from transduced human hematopoietic stem/progenitor cells. Mol Ther. 2013 May; 21(5):1044-54. PMID: 23380815.
      View in: PubMed   Mentions: 21     Fields:    Translation:HumansAnimalsCells
    223. Host immunity contributes to the anti-melanoma activity of BRAF inhibitors. J Clin Invest. 2013 Mar; 123(3):1371-81. PMID: 23454771.
      View in: PubMed   Mentions: 106     Fields:    Translation:HumansAnimalsCells
    224. Dendritic cell-based immunotherapy in prevention and treatment of renal cell carcinoma: efficacy, safety, and activity of Ad-GM·CAIX in immunocompetent mouse models. J Immunother. 2013 Feb; 36(2):102-11. PMID: 23377663.
      View in: PubMed   Mentions: 11     Fields:    Translation:AnimalsCells
    225. Effect of dabrafenib on melanoma cell lines harbouring the BRAF(V600D/R) mutations. BMC Cancer. 2013 Jan 14; 13:17. PMID: 23317446.
      View in: PubMed   Mentions: 9     Fields:    Translation:HumansCells
    226. Phase III randomized clinical trial comparing tremelimumab with standard-of-care chemotherapy in patients with advanced melanoma. J Clin Oncol. 2013 Feb 10; 31(5):616-22. PMID: 23295794.
      View in: PubMed   Mentions: 212     Fields:    Translation:HumansCTClinical Trials
    227. Phase II study of the MEK1/MEK2 inhibitor Trametinib in patients with metastatic BRAF-mutant cutaneous melanoma previously treated with or without a BRAF inhibitor. J Clin Oncol. 2013 Feb 01; 31(4):482-9. PMID: 23248257.
      View in: PubMed   Mentions: 150     Fields:    Translation:HumansCTClinical Trials
    228. Targeting oncogenic drivers and the immune system in melanoma. J Clin Oncol. 2013 Feb 01; 31(4):499-506. PMID: 23248252.
      View in: PubMed   Mentions: 29     Fields:    Translation:HumansCells
    229. Phase II trial of sorafenib in combination with carboplatin and paclitaxel in patients with metastatic uveal melanoma: SWOG S0512. PLoS One. 2012; 7(11):e48787. PMID: 23226204.
      View in: PubMed   Mentions: 19     Fields:    Translation:HumansCTClinical Trials
    230. Safety profile and pharmacokinetic analyses of the anti-CTLA4 antibody tremelimumab administered as a one hour infusion. J Transl Med. 2012 Nov 21; 10:236. PMID: 23171508.
      View in: PubMed   Mentions: 13     Fields:    Translation:HumansCTClinical Trials
    231. Cancer therapy: Tumours switch to resist. Nature. 2012 Oct 18; 490(7420):347-8. PMID: 23051745.
      View in: PubMed   Mentions: 4     Fields:    Translation:HumansAnimalsCells
    232. Tumour micro-environment elicits innate resistance to RAF inhibitors through HGF secretion. Nature. 2012 Jul 26; 487(7408):500-4. PMID: 22763439.
      View in: PubMed   Mentions: 625     Fields:    Translation:HumansCells
    233. Widespread potential for growth-factor-driven resistance to anticancer kinase inhibitors. Nature. 2012 Jul 26; 487(7408):505-9. PMID: 22763448.
      View in: PubMed   Mentions: 479     Fields:    Translation:HumansCells
    234. BRAF(L597) mutations in melanoma are associated with sensitivity to MEK inhibitors. Cancer Discov. 2012 Sep; 2(9):791-7. PMID: 22798288.
      View in: PubMed   Mentions: 83     Fields:    Translation:HumansCells
    235. Future perspectives in melanoma research. Meeting report from the "Melanoma research: a bridge from Naples to the World. Napoli, December 5th-6th 2011". J Transl Med. 2012 Jul 04; 10:83. PMID: 22551296.
      View in: PubMed   Mentions: 4     Fields:    Translation:HumansAnimals
    236. Glucose deprivation activates a metabolic and signaling amplification loop leading to cell death. Mol Syst Biol. 2012 Jun 26; 8:589. PMID: 22735335.
      View in: PubMed   Mentions: 53     Fields:    Translation:HumansCells
    237. BRAF inhibitor vemurafenib improves the antitumor activity of adoptive cell immunotherapy. Cancer Res. 2012 Aug 15; 72(16):3928-37. PMID: 22693252.
      View in: PubMed   Mentions: 88     Fields:    Translation:HumansAnimalsCells
    238. Tumor immunotherapy directed at PD-1. N Engl J Med. 2012 Jun 28; 366(26):2517-9. PMID: 22658126.
      View in: PubMed   Mentions: 193     Fields:    Translation:Humans
    239. Immunoediting the cancer genome--a new approach for personalized cancer therapy? Pigment Cell Melanoma Res. 2012 May; 25(3):297-8. PMID: 22629569.
      View in: PubMed   Mentions: 2     Fields:    Translation:HumansAnimalsCells
    240. Antitumor effects of the investigational selective MEK inhibitor TAK733 against cutaneous and uveal melanoma cell lines. Mol Cancer. 2012 Apr 19; 11:22. PMID: 22515704.
      View in: PubMed   Mentions: 32     Fields:    Translation:HumansCells
    241. Preexisting MEK1 exon 3 mutations in V600E/KBRAF melanomas do not confer resistance to BRAF inhibitors. Cancer Discov. 2012 May; 2(5):414-24. PMID: 22588879.
      View in: PubMed   Mentions: 36     Fields:    Translation:HumansCells
    242. Marked, homogeneous, and early [18F]fluorodeoxyglucose-positron emission tomography responses to vemurafenib in BRAF-mutant advanced melanoma. J Clin Oncol. 2012 May 10; 30(14):1628-34. PMID: 22454415.
      View in: PubMed   Mentions: 54     Fields:    Translation:HumansCTClinical Trials
    243. Melanoma whole-exome sequencing identifies (V600E)B-RAF amplification-mediated acquired B-RAF inhibitor resistance. Nat Commun. 2012 Mar 06; 3:724. PMID: 22395615.
      View in: PubMed   Mentions: 239     Fields:    Translation:HumansCells
    244. Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib. N Engl J Med. 2012 Feb 23; 366(8):707-14. PMID: 22356324.
      View in: PubMed   Mentions: 700     Fields:    Translation:HumansCTClinical Trials
    245. The HSP90 inhibitor XL888 overcomes BRAF inhibitor resistance mediated through diverse mechanisms. Clin Cancer Res. 2012 May 01; 18(9):2502-14. PMID: 22351686.
      View in: PubMed   Mentions: 64     Fields:    Translation:HumansAnimalsCells
    246. RAS mutations in cutaneous squamous-cell carcinomas in patients treated with BRAF inhibitors. N Engl J Med. 2012 Jan 19; 366(3):207-15. PMID: 22256804.
      View in: PubMed   Mentions: 308     Fields:    Translation:HumansAnimalsCTClinical Trials
    247. Combination Therapies Building on the Efficacy of CTLA4 and BRAF Inhibitors for Metastatic Melanoma. Am Soc Clin Oncol Educ Book. 2012; 675-8. PMID: 24451817.
      View in: PubMed   Mentions:    Fields:    
    248. Defining the critical hurdles in cancer immunotherapy. J Transl Med. 2011 Dec 14; 9:214. PMID: 22168571.
      View in: PubMed   Mentions: 63     Fields:    Translation:Humans
    249. Reversing melanoma cross-resistance to BRAF and MEK inhibitors by co-targeting the AKT/mTOR pathway. PLoS One. 2011; 6(12):e28973. PMID: 22194965.
      View in: PubMed   Mentions: 91     Fields:    Translation:HumansCells
    250. Meeting report from the 2011 International Melanoma Congress, Tampa, Florida. Pigment Cell Melanoma Res. 2012 Jan; 25(1):E1-11. PMID: 22117673.
      View in: PubMed   Mentions: 5     Fields:    Translation:Humans
    251. New challenges in endpoints for drug development in advanced melanoma. Clin Cancer Res. 2012 Jan 15; 18(2):336-41. PMID: 22142824.
      View in: PubMed   Mentions: 27     Fields:    Translation:Humans
    252. Antitumor activity from antigen-specific CD8 T cells generated in vivo from genetically engineered human hematopoietic stem cells. Proc Natl Acad Sci U S A. 2011 Dec 20; 108(51):E1408-16. PMID: 22123951.
      View in: PubMed   Mentions: 52     Fields:    Translation:HumansAnimalsCells
    253. RAF inhibitor resistance is mediated by dimerization of aberrantly spliced BRAF(V600E). Nature. 2011 Nov 23; 480(7377):387-90. PMID: 22113612.
      View in: PubMed   Mentions: 546     Fields:    Translation:HumansAnimalsCells
    254. Anti-CTLA4 monoclonal antibodies: the past and the future in clinical application. J Transl Med. 2011 Nov 13; 9:196. PMID: 22077981.
      View in: PubMed   Mentions: 20     Fields:    Translation:HumansAnimals
    255. Decitabine immunosensitizes human gliomas to NY-ESO-1 specific T lymphocyte targeting through the Fas/Fas ligand pathway. J Transl Med. 2011 Nov 07; 9:192. PMID: 22060015.
      View in: PubMed   Mentions: 19     Fields:    Translation:HumansCells
    256. Immunomodulation by imiquimod in patients with high-risk primary melanoma. J Invest Dermatol. 2012 Jan; 132(1):163-9. Narayan R, Nguyen H, Bentow JJ, Moy L, Lee DK, Greger S, Haskell J, Vanchinathan V, Chang PL, Tsui S, Konishi T, Comin-Anduix B, Dauphine C, Vargas HI, Economou JS, Ribas A, Bruhn KW, Craft N. PMID: 21850019.
      View in: PubMed   Mentions: 24     Fields:    Translation:HumansCells
    257. Combinatorial treatments that overcome PDGFRß-driven resistance of melanoma cells to V600EB-RAF inhibition. Cancer Res. 2011 Aug 01; 71(15):5067-74. Shi H, Kong X, Ribas A, Lo RS. PMID: 21803746.
      View in: PubMed   Mentions: 80     Fields:    Translation:HumansCells
    258. A mechanistic proof-of-concept clinical trial with JX-594, a targeted multi-mechanistic oncolytic poxvirus, in patients with metastatic melanoma. Mol Ther. 2011 Oct; 19(10):1913-22. PMID: 21772252.
      View in: PubMed   Mentions: 60     Fields:    Translation:HumansCellsCTClinical Trials
    259. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med. 2011 Jun 30; 364(26):2507-16. Chapman PB, Hauschild A, Robert C, Haanen JB, Ascierto P, Larkin J, Dummer R, Garbe C, Testori A, Maio M, Hogg D, Lorigan P, Lebbe C, Jouary T, Schadendorf D, Ribas A, O'Day SJ, Sosman JA, Kirkwood JM, Eggermont AM, Dreno B, Nolop K, Li J, Nelson B, Hou J, Lee RJ, Flaherty KT, McArthur GA. PMID: 21639808.
      View in: PubMed   Mentions: 2330     Fields:    Translation:HumansCTClinical Trials
    260. BRAF targeted therapy changes the treatment paradigm in melanoma. Nat Rev Clin Oncol. 2011 05 24; 8(7):426-33. PMID: 21606968.
      View in: PubMed   Mentions: 82     Fields:    Translation:Humans
    261. Combination therapy with vemurafenib (PLX4032/RG7204) and metformin in melanoma cell lines with distinct driver mutations. J Transl Med. 2011 May 24; 9:76. PMID: 21609436.
      View in: PubMed   Mentions: 35     Fields:    Translation:HumansCells
    262. A clinical microchip for evaluation of single immune cells reveals high functional heterogeneity in phenotypically similar T cells. Nat Med. 2011 Jun; 17(6):738-43. PMID: 21602800.
      View in: PubMed   Mentions: 129     Fields:    Translation:HumansCells
    263. CTLA4 blockade induces frequent tumor infiltration by activated lymphocytes regardless of clinical responses in humans. Clin Cancer Res. 2011 Jun 15; 17(12):4101-9. Huang RR, Jalil J, Economou JS, Chmielowski B, Koya RC, Mok S, Sazegar H, Seja E, Villanueva A, Gomez-Navarro J, Glaspy JA, Cochran AJ, Ribas A. PMID: 21558401.
      View in: PubMed   Mentions: 60     Fields:    Translation:HumansCellsCTClinical Trials
    264. A beta-camera integrated with a microfluidic chip for radioassays based on real-time imaging of glycolysis in small cell populations. J Nucl Med. 2011 May; 52(5):815-21. PMID: 21536929.
      View in: PubMed   Mentions: 13     Fields:    Translation:HumansCells
    265. Future perspectives in melanoma research. Meeting report from the "Melanoma Research: a bridge Naples-USA. Naples, December 6th-7th 2010". J Transl Med. 2011 Mar 26; 9:32. Ascierto PA, De Maio E, Bertuzzi S, Palmieri G, Halaban R, Hendrix M, Kashani-sabet M, Ferrone S, Wang E, Cochran A, Rivoltini L, Lee PP, Fox BA, Kirkwood JM, Ullmann CD, Lehmann FF, Sznol M, Schwartzentruber DJ, Maio M, Flaherty K, Galon J, Ribas A, Yang J, Stroncek DF, Mozzillo N, Marincola FM. PMID: 21439082.
      View in: PubMed   Mentions: 6     Fields:    Translation:HumansAnimalsCells
    266. Intra-lymph node prime-boost vaccination against Melan A and tyrosinase for the treatment of metastatic melanoma: results of a phase 1 clinical trial. Clin Cancer Res. 2011 May 01; 17(9):2987-96. PMID: 21385924.
      View in: PubMed   Mentions: 24     Fields:    Translation:HumansPHPublic HealthCTClinical Trials
    267. PTEN loss confers BRAF inhibitor resistance to melanoma cells through the suppression of BIM expression. Cancer Res. 2011 Apr 01; 71(7):2750-60. Paraiso KH, Xiang Y, Rebecca VW, Abel EV, Chen YA, Munko AC, Wood E, Fedorenko IV, Sondak VK, Anderson AR, Ribas A, Palma MD, Nathanson KL, Koomen JM, Messina JL, Smalley KS. PMID: 21317224.
      View in: PubMed   Mentions: 213     Fields:    Translation:HumansCells
    268. The oncogenic BRAF kinase inhibitor PLX4032/RG7204 does not affect the viability or function of human lymphocytes across a wide range of concentrations. Clin Cancer Res. 2010 Dec 15; 16(24):6040-8. Comin-Anduix B, Chodon T, Sazegar H, Matsunaga D, Mock S, Jalil J, Escuin-Ordinas H, Chmielowski B, Koya RC, Ribas A. PMID: 21169256.
      View in: PubMed   Mentions: 68     Fields:    Translation:HumansCells
    269. Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation. Nature. 2010 Dec 16; 468(7326):973-7. Nazarian R, Shi H, Wang Q, Kong X, Koya RC, Lee H, Chen Z, Lee MK, Attar N, Sazegar H, Chodon T, Nelson SF, McArthur G, Sosman JA, Ribas A, Lo RS. PMID: 21107323.
      View in: PubMed   Mentions: 837     Fields:    Translation:HumansCells
    270. siRNA knockdown of ribonucleotide reductase inhibits melanoma cell line proliferation alone or synergistically with temozolomide. J Invest Dermatol. 2011 Feb; 131(2):453-60. Zuckerman JE, Hsueh T, Koya RC, Davis ME, Ribas A. PMID: 20944646.
      View in: PubMed   Mentions: 14     Fields:    Translation:HumansCells
    271. The impact of ex vivo clinical grade activation protocols on human T-cell phenotype and function for the generation of genetically modified cells for adoptive cell transfer therapy. J Immunother. 2010 Oct; 33(8):759-68. Tumeh PC, Koya RC, Chodon T, Graham NA, Graeber TG, Comin-Anduix B, Ribas A. PMID: 20842061.
      View in: PubMed   Mentions: 9     Fields:    Translation:HumansCells
    272. Clinical development of the anti-CTLA-4 antibody tremelimumab. Semin Oncol. 2010 Oct; 37(5):450-4. Ribas A. PMID: 21074059.
      View in: PubMed   Mentions: 33     Fields:    Translation:Humans
    273. CD40 expression by human melanocytic lesions and melanoma cell lines and direct CD40 targeting with the therapeutic anti-CD40 antibody CP-870,893. J Immunother. 2010 Oct; 33(8):810-6. Kalbasi A, Fonsatti E, Natali PG, Altomonte M, Bertocci E, Cutaia O, Calabrò L, Chiou M, Tap W, Chmielowski B, Maio M, Ribas A. PMID: 20842056.
      View in: PubMed   Mentions: 8     Fields:    Translation:HumansCells
    274. Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma. Nature. 2010 Sep 30; 467(7315):596-9. Bollag G, Hirth P, Tsai J, Zhang J, Ibrahim PN, Cho H, Spevak W, Zhang C, Zhang Y, Habets G, Burton EA, Wong B, Tsang G, West BL, Powell B, Shellooe R, Marimuthu A, Nguyen H, Zhang KY, Artis DR, Schlessinger J, Su F, Higgins B, Iyer R, D'Andrea K, Koehler A, Stumm M, Lin PS, Lee RJ, Grippo J, Puzanov I, Kim KB, Ribas A, McArthur GA, Sosman JA, Chapman PB, Flaherty KT, Xu X, Nathanson KL, Nolop K. PMID: 20823850.
      View in: PubMed   Mentions: 606     Fields:    Translation:HumansAnimalsCellsCTClinical Trials
    275. Multicenter phase II study of matured dendritic cells pulsed with melanoma cell line lysates in patients with advanced melanoma. J Transl Med. 2010 Sep 27; 8:89. Ribas A, Camacho LH, Lee SM, Hersh EM, Brown CK, Richards JM, Rodriguez MJ, Prieto VG, Glaspy JA, Oseguera DK, Hernandez J, Villanueva A, Chmielowski B, Mitsky P, Bercovici N, Wasserman E, Landais D, Ross MI. PMID: 20875102.
      View in: PubMed   Mentions: 9     Fields:    Translation:HumansCellsCTClinical Trials
    276. Modulation of cell signaling networks after CTLA4 blockade in patients with metastatic melanoma. PLoS One. 2010 Sep 15; 5(9):e12711. Comin-Anduix B, Sazegar H, Chodon T, Matsunaga D, Jalil J, von Euw E, Escuin-Ordinas H, Balderas R, Chmielowski B, Gomez-Navarro J, Koya RC, Ribas A. PMID: 20856802.
      View in: PubMed   Mentions: 12     Fields:    Translation:HumansCellsCTClinical Trials
    277. Inhibition of mutated, activated BRAF in metastatic melanoma. N Engl J Med. 2010 Aug 26; 363(9):809-19. Flaherty KT, Puzanov I, Kim KB, Ribas A, McArthur GA, Sosman JA, O'Dwyer PJ, Lee RJ, Grippo JF, Nolop K, Chapman PB. PMID: 20818844.
      View in: PubMed   Mentions: 1264     Fields:    Translation:HumansCTClinical Trials
    278. Meeting report from the Third Global Workshop on Melanoma. Pigment Cell Melanoma Res. 2010 Oct; 23(5):e1-7. Agarwala SS, di Pietro A, Flaherty KT, Garbe C, Grob JJ, Kashani-Sabet M, Kirkwood JM, Leachman S, Messina J, O'Day S, Ribas A, Sondak V. PMID: 20718940.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    279. A phase 1-2 study of imexon plus dacarbazine in patients with unresectable metastatic melanoma. Cancer. 2010 Aug 01; 116(15):3683-91. Weber JS, Samlowski WE, Gonzalez R, Ribas A, Stephenson J, O'Day S, Sato T, Dorr R, Grenier K, Hersh E. PMID: 20564083.
      View in: PubMed   Mentions: 4     Fields:    Translation:HumansCTClinical Trials
    280. Human antigen-specific regulatory T cells generated by T cell receptor gene transfer. PLoS One. 2010 Jul 22; 5(7):e11726. Brusko TM, Koya RC, Zhu S, Lee MR, Putnam AL, McClymont SA, Nishimura MI, Han S, Chang LJ, Atkinson MA, Ribas A, Bluestone JA. PMID: 20668510.
      View in: PubMed   Mentions: 47     Fields:    Translation:HumansAnimalsCells
    281. Kinetic phases of distribution and tumor targeting by T cell receptor engineered lymphocytes inducing robust antitumor responses. Proc Natl Acad Sci U S A. 2010 Aug 10; 107(32):14286-91. Koya RC, Mok S, Comin-Anduix B, Chodon T, Radu CG, Nishimura MI, Witte ON, Ribas A. PMID: 20624956.
      View in: PubMed   Mentions: 37     Fields:    Translation:HumansAnimalsCells
    282. Current experience with CTLA4-blocking monoclonal antibodies for the treatment of solid tumors. J Immunother. 2010 Jul-Aug; 33(6):557-69. Agarwala SS, Ribas A. PMID: 20551840.
      View in: PubMed   Mentions: 13     Fields:    Translation:HumansAnimalsCells
    283. MHC-I-restricted melanoma antigen specific TCR-engineered human CD4+ T cells exhibit multifunctional effector and helper responses, in vitro. Clin Immunol. 2010 Sep; 136(3):338-47. Ray S, Chhabra A, Chakraborty NG, Hegde U, Dorsky DI, Chodon T, von Euw E, Comin-Anduix B, Koya RC, Ribas A, Economou JS, Rosenberg SA, Mukherji B. PMID: 20547105.
      View in: PubMed   Mentions: 16     Fields:    Translation:HumansCells
    284. Differential sensitivity of melanoma cell lines with BRAFV600E mutation to the specific Raf inhibitor PLX4032. J Transl Med. 2010 Apr 20; 8:39. Søndergaard JN, Nazarian R, Wang Q, Guo D, Hsueh T, Mok S, Sazegar H, MacConaill LE, Barretina JG, Kehoe SM, Attar N, von Euw E, Zuckerman JE, Chmielowski B, Comin-Anduix B, Koya RC, Mischel PS, Lo RS, Ribas A. PMID: 20406486.
      View in: PubMed   Mentions: 102     Fields:    Translation:HumansAnimalsCells
    285. Imaging of CTLA4 blockade-induced cell replication with (18)F-FLT PET in patients with advanced melanoma treated with tremelimumab. J Nucl Med. 2010 Mar; 51(3):340-6. Ribas A, Benz MR, Allen-Auerbach MS, Radu C, Chmielowski B, Seja E, Williams JL, Gomez-Navarro J, McCarthy T, Czernin J. PMID: 20150263.
      View in: PubMed   Mentions: 26     Fields:    Translation:HumansCTClinical Trials
    286. Immune rejection in a humanized model of murine prostate cancer. Anticancer Res. 2010 Feb; 30(2):409-14. Schaue D, Koya RC, Liao YP, Ribas A, McBride WH. PMID: 20332447.
      View in: PubMed   Mentions: 1     Fields:    Translation:HumansAnimalsCells
    287. Overcoming barriers to programming a therapeutic cellular immune response to fight melanoma. Pigment Cell Melanoma Res. 2010 Apr; 23(2):288-9. Baltimore D, Witte ON, Yang L, Economou J, Ribas A. PMID: 20067554.
      View in: PubMed   Mentions: 1     Fields:    Translation:HumansCells
    288. A phase 2 clinical trial of nab-paclitaxel in previously treated and chemotherapy-naive patients with metastatic melanoma. Cancer. 2010 Jan 01; 116(1):155-63. Hersh EM, O'Day SJ, Ribas A, Samlowski WE, Gordon MS, Shechter DE, Clawson AA, Gonzalez R. PMID: 19877111.
      View in: PubMed   Mentions: 31     Fields:    Translation:HumansCTClinical Trials
    289. Do we need a different set of response assessment criteria for tumor immunotherapy? Clin Cancer Res. 2009 Dec 01; 15(23):7116-8. Ribas A, Chmielowski B, Glaspy JA. PMID: 19934296.
      View in: PubMed   Mentions: 37     Fields:    Translation:Humans
    290. Obstacles to and opportunities for more effective peptide-based therapeutic immunization in human melanoma. Clin Dermatol. 2009 Nov-Dec; 27(6):603-13. Ray S, Chhabra A, Mehrotra S, Chakraborty NG, Ribas A, Economou J, Mukherji B. PMID: 19880048.
      View in: PubMed   Mentions: 5     Fields:    Translation:HumansCellsPHPublic Health
    291. Enhanced antitumor activity induced by adoptive T-cell transfer and adjunctive use of the histone deacetylase inhibitor LAQ824. Cancer Res. 2009 Nov 15; 69(22):8693-9. Vo DD, Prins RM, Begley JL, Donahue TR, Morris LF, Bruhn KW, de la Rocha P, Yang MY, Mok S, Garban HJ, Craft N, Economou JS, Marincola FM, Wang E, Ribas A. PMID: 19861533.
      View in: PubMed   Mentions: 62     Fields:    Translation:AnimalsCells
    292. Dendritic cell vaccination combined with CTLA4 blockade in patients with metastatic melanoma. Clin Cancer Res. 2009 Oct 01; 15(19):6267-76. Ribas A, Comin-Anduix B, Chmielowski B, Jalil J, de la Rocha P, McCannel TA, Ochoa MT, Seja E, Villanueva A, Oseguera DK, Straatsma BR, Cochran AJ, Glaspy JA, Hui L, Marincola FM, Wang E, Economou JS, Gomez-Navarro J. PMID: 19789309.
      View in: PubMed   Mentions: 71     Fields:    Translation:HumansCellsCTClinical Trials
    293. Phase I/II open-label study of the biologic effects of the interleukin-2 immunocytokine EMD 273063 (hu14.18-IL2) in patients with metastatic malignant melanoma. J Transl Med. 2009 Jul 29; 7:68. Ribas A, Kirkwood JM, Atkins MB, Whiteside TL, Gooding W, Kovar A, Gillies SD, Kashala O, Morse MA. PMID: 19640287.
      View in: PubMed   Mentions: 15     Fields:    Translation:HumansCTClinical Trials
    294. Modular nucleic acid assembled p/MHC microarrays for multiplexed sorting of antigen-specific T cells. J Am Chem Soc. 2009 Jul 22; 131(28):9695-703. Kwong GA, Radu CG, Hwang K, Shu CJ, Ma C, Koya RC, Comin-Anduix B, Hadrup SR, Bailey RC, Witte ON, Schumacher TN, Ribas A, Heath JR. PMID: 19552409.
      View in: PubMed   Mentions: 32     Fields:    Translation:HumansAnimalsCells
    295. Meeting report: consensus from the first and second Global Workshops in Melanoma November 19-20, 2008. Pigment Cell Melanoma Res. 2009 Oct; 22(5):532-43. Agarwala SS, Becker JC, Eggermont AM, Flaherty KT, Garbe C, Goldstein AM, Halpern A, Kashani-Sabet M, Hauschild A, Kirkwood JM, Leachman S, Lorigan P, McMahon M, Messina J, Ribas A, Samlowski WE, Schadendorf D, Sondak VK. PMID: 19659612.
      View in: PubMed   Mentions: 2     Fields:    Translation:HumansCells
    296. Emerging concepts in biomarker discovery; the US-Japan Workshop on Immunological Molecular Markers in Oncology. J Transl Med. 2009 Jun 17; 7:45. Tahara H, Sato M, Thurin M, Wang E, Butterfield LH, Disis ML, Fox BA, Lee PP, Khleif SN, Wigginton JM, Ambs S, Akutsu Y, Chaussabel D, Doki Y, Eremin O, Fridman WH, Hirohashi Y, Imai K, Jacobson J, Jinushi M, Kanamoto A, Kashani-Sabet M, Kato K, Kawakami Y, Kirkwood JM, Kleen TO, Lehmann PV, Liotta L, Lotze MT, Maio M, Malyguine A, Masucci G, Matsubara H, Mayrand-Chung S, Nakamura K, Nishikawa H, Palucka AK, Petricoin EF, Pos Z, Ribas A, Rivoltini L, Sato N, Shiku H, Slingluff CL, Streicher H, Stroncek DF, Takeuchi H, Toyota M, Wada H, Wu X, Wulfkuhle J, Yaguchi T, Zeskind B, Zhao Y, Zocca MB, Marincola FM. PMID: 19534815.
      View in: PubMed   Mentions: 24     Fields:    Translation:Humans
    297. CTLA4 blockade increases Th17 cells in patients with metastatic melanoma. J Transl Med. 2009 May 20; 7:35. von Euw E, Chodon T, Attar N, Jalil J, Koya RC, Comin-Anduix B, Ribas A. PMID: 19457253.
      View in: PubMed   Mentions: 38     Fields:    Translation:HumansCellsCTClinical Trials
    298. Interferon alfa in the postsurgical management of high-risk melanoma: is it worth it? J Clin Oncol. 2009 Jun 20; 27(18):2896-7. Glaspy J, Ribas A, Chmielowski B. PMID: 19433677.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    299. HMGB1 mediates endogenous TLR2 activation and brain tumor regression. PLoS Med. 2009 Jan 13; 6(1):e10. Curtin JF, Liu N, Candolfi M, Xiong W, Assi H, Yagiz K, Edwards MR, Michelsen KS, Kroeger KM, Liu C, Muhammad AK, Clark MC, Arditi M, Comin-Anduix B, Ribas A, Lowenstein PR, Castro MG. PMID: 19143470.
      View in: PubMed   Mentions: 158     Fields:    Translation:HumansAnimalsCells
    300. Phase I/II trial of tremelimumab in patients with metastatic melanoma. J Clin Oncol. 2009 Mar 01; 27(7):1075-81. Camacho LH, Antonia S, Sosman J, Kirkwood JM, Gajewski TF, Redman B, Pavlov D, Bulanhagui C, Bozon VA, Gomez-Navarro J, Ribas A. PMID: 19139427.
      View in: PubMed   Mentions: 89     Fields:    Translation:HumansCTClinical Trials
    301. Intratumoral immune cell infiltrates, FoxP3, and indoleamine 2,3-dioxygenase in patients with melanoma undergoing CTLA4 blockade. Clin Cancer Res. 2009 Jan 01; 15(1):390-9. Ribas A, Comin-Anduix B, Economou JS, Donahue TR, de la Rocha P, Morris LF, Jalil J, Dissette VB, Shintaku IP, Glaspy JA, Gomez-Navarro J, Cochran AJ. PMID: 19118070.
      View in: PubMed   Mentions: 47     Fields:    Translation:HumansCells
    302. Quantitative PET reporter gene imaging of CD8+ T cells specific for a melanoma-expressed self-antigen. Int Immunol. 2009 Feb; 21(2):155-65. Shu CJ, Radu CG, Shelly SM, Vo DD, Prins R, Ribas A, Phelps ME, Witte ON. PMID: 19106231.
      View in: PubMed   Mentions: 21     Fields:    Translation:AnimalsCells
    303. A systematic approach to biomarker discovery; preamble to "the iSBTc-FDA taskforce on immunotherapy biomarkers". J Transl Med. 2008 Dec 23; 6:81. Butterfield LH, Disis ML, Fox BA, Lee PP, Khleif SN, Thurin M, Trinchieri G, Wang E, Wigginton J, Chaussabel D, Coukos G, Dhodapkar M, Håkansson L, Janetzki S, Kleen TO, Kirkwood JM, Maccalli C, Maecker H, Maio M, Malyguine A, Masucci G, Palucka AK, Potter DM, Ribas A, Rivoltini L, Schendel D, Seliger B, Selvan S, Slingluff CL, Stroncek DF, Streicher H, Wu X, Zeskind B, Zhao Y, Zocca MB, Zwierzina H, Marincola FM. PMID: 19105846.
      View in: PubMed   Mentions: 27     Fields:    Translation:Humans
    304. Immunosensitization with a Bcl-2 small molecule inhibitor. Cancer Immunol Immunother. 2009 May; 58(5):699-708. Begley J, Vo DD, Morris LF, Bruhn KW, Prins RM, Mok S, Koya RC, Garban HJ, Comin-Anduix B, Craft N, Ribas A. PMID: 18807035.
      View in: PubMed   Mentions: 6     Fields:    Translation:HumansAnimalsCells
    305. T-cell responses to survivin in cancer patients undergoing radiation therapy. Clin Cancer Res. 2008 Aug 01; 14(15):4883-90. Schaue D, Comin-Anduix B, Ribas A, Zhang L, Goodglick L, Sayre JW, Debucquoy A, Haustermans K, McBride WH. PMID: 18676762.
      View in: PubMed   Mentions: 52     Fields:    Translation:HumansCells
    306. CD4+CD25- T cells transduced to express MHC class I-restricted epitope-specific TCR synthesize Th1 cytokines and exhibit MHC class I-restricted cytolytic effector function in a human melanoma model. J Immunol. 2008 Jul 15; 181(2):1063-70. Chhabra A, Yang L, Wang P, Comin-Anduix B, Das R, Chakraborty NG, Ray S, Mehrotra S, Yang H, Hardee CL, Hollis R, Dorsky DI, Koya R, Kohn DB, Ribas A, Economou JS, Baltimore D, Mukherji B. PMID: 18606658.
      View in: PubMed   Mentions: 16     Fields:    Translation:HumansCells
    307. Targeted therapies to improve tumor immunotherapy. Clin Cancer Res. 2008 Jul 15; 14(14):4385-91. Begley J, Ribas A. PMID: 18628452.
      View in: PubMed   Mentions: 28     Fields:    Translation:Humans
    308. PET imaging of cancer immunotherapy. J Nucl Med. 2008 Jun; 49(6):865-8. Tumeh PC, Radu CG, Ribas A. PMID: 18511842.
      View in: PubMed   Mentions: 12     Fields:    Translation:Humans
    309. Detailed analysis of immunologic effects of the cytotoxic T lymphocyte-associated antigen 4-blocking monoclonal antibody tremelimumab in peripheral blood of patients with melanoma. J Transl Med. 2008 May 01; 6:22. Comin-Anduix B, Lee Y, Jalil J, Algazi A, de la Rocha P, Camacho LH, Bozon VA, Bulanhagui CA, Seja E, Villanueva A, Straatsma BR, Gualberto A, Economou JS, Glaspy JA, Gomez-Navarro J, Ribas A. PMID: 18452610.
      View in: PubMed   Mentions: 36     Fields:    Translation:HumansCellsCTClinical Trials
    310. Adenovirus MART-1-engineered autologous dendritic cell vaccine for metastatic melanoma. J Immunother. 2008 Apr; 31(3):294-309. Butterfield LH, Comin-Anduix B, Vujanovic L, Lee Y, Dissette VB, Yang JQ, Vu HT, Seja E, Oseguera DK, Potter DM, Glaspy JA, Economou JS, Ribas A. PMID: 18317358.
      View in: PubMed   Mentions: 44     Fields:    Translation:HumansCellsCTClinical Trials
    311. Anti-tumor activity and trafficking of self, tumor-specific T cells against tumors located in the brain. Cancer Immunol Immunother. 2008 Sep; 57(9):1279-89. Prins RM, Shu CJ, Radu CG, Vo DD, Khan-Farooqi H, Soto H, Yang MY, Lin MS, Shelly S, Witte ON, Ribas A, Liau LM. PMID: 18253732.
      View in: PubMed   Mentions: 31     Fields:    Translation:HumansAnimalsCells
    312. Overcoming immunologic tolerance to melanoma: targeting CTLA-4 with tremelimumab (CP-675,206). Oncologist. 2008; 13 Suppl 4:10-5. Ribas A. PMID: 19001146.
      View in: PubMed   Mentions: 16     Fields:    Translation:Humans
    313. Therapeutic cancer vaccines. Surg Oncol Clin N Am. 2007 Oct; 16(4):819-31, ix. Morris LF, Ribas A. PMID: 18022546.
      View in: PubMed   Mentions: 5     Fields:    Translation:HumansAnimalsCells
    314. Anti-CTLA4 Antibody Clinical Trials in Melanoma. Update Cancer Ther. 2007 Sep; 2(3):133-139. Ribas A. PMID: 19543441.
      View in: PubMed   Mentions:
    315. Tremelimumab (CP-675,206), a cytotoxic T lymphocyte associated antigen 4 blocking monoclonal antibody in clinical development for patients with cancer. Oncologist. 2007 Jul; 12(7):873-83. Ribas A, Hanson DC, Noe DA, Millham R, Guyot DJ, Bernstein SH, Canniff PC, Sharma A, Gomez-Navarro J. PMID: 17673618.
      View in: PubMed   Mentions: 51     Fields:    Translation:Humans
    316. Spontaneous and vaccine induced AFP-specific T cell phenotypes in subjects with AFP-positive hepatocellular cancer. Cancer Immunol Immunother. 2007 Dec; 56(12):1931-43. Butterfield LH, Ribas A, Potter DM, Economou JS. PMID: 17522860.
      View in: PubMed   Mentions: 19     Fields:    Translation:HumansCells
    317. Metastatic melanoma to the kidney presenting with renal vein tumor thrombus. Urology. 2007 May; 69(5):982.e7-9. Klatte T, Rao JY, Ribas A, Pantuck AJ. PMID: 17482952.
      View in: PubMed   Mentions: 3     Fields:    Translation:HumansCells
    318. Surveillance of the eye and vision in clinical trials of CP-675,206 for metastatic melanoma. Am J Ophthalmol. 2007 Jun; 143(6):958-969. Straatsma BR, Nusinowitz S, Young TA, Gordon LK, Chun MW, Rosen C, Seja E, Economou JS, Glaspy JA, Bozon V, Gomez-Navarro J, Ribas A. PMID: 17434437.
      View in: PubMed   Mentions: 4     Fields:    Translation:HumansCellsCTClinical Trials
    319. Lentiviral vector-mediated autonomous differentiation of mouse bone marrow cells into immunologically potent dendritic cell vaccines. Mol Ther. 2007 May; 15(5):971-80. Koya RC, Kimura T, Ribas A, Rozengurt N, Lawson GW, Faure-Kumar E, Wang HJ, Herschman H, Kasahara N, Stripecke R. PMID: 17375074.
      View in: PubMed   Mentions: 11     Fields:    Translation:AnimalsCells
    320. NK and CD4 cells collaborate to protect against melanoma tumor formation in the brain. J Immunol. 2006 Dec 15; 177(12):8448-55. Prins RM, Vo DD, Khan-Farooqi H, Yang MY, Soto H, Economou JS, Liau LM, Ribas A. PMID: 17142742.
      View in: PubMed   Mentions: 24     Fields:    Translation:AnimalsCells
    321. Update on immunotherapy for melanoma. J Natl Compr Canc Netw. 2006 Aug; 4(7):687-94. Ribas A. PMID: 16884670.
      View in: PubMed   Mentions: 8     Fields:    Translation:Humans
    322. A phase I/II trial testing immunization of hepatocellular carcinoma patients with dendritic cells pulsed with four alpha-fetoprotein peptides. Clin Cancer Res. 2006 May 01; 12(9):2817-25. Butterfield LH, Ribas A, Dissette VB, Lee Y, Yang JQ, De la Rocha P, Duran SD, Hernandez J, Seja E, Potter DM, McBride WH, Finn R, Glaspy JA, Economou JS. PMID: 16675576.
      View in: PubMed   Mentions: 66     Fields:    Translation:HumansCellsCTClinical Trials
    323. Immunosensitization of tumor cells to dendritic cell-activated immune responses with the proteasome inhibitor bortezomib (PS-341, Velcade). J Immunol. 2006 Apr 15; 176(8):4757-65. Schumacher LY, Vo DD, Garban HJ, Comin-Anduix B, Owens SK, Dissette VB, Glaspy JA, McBride WH, Bonavida B, Economou JS, Ribas A. PMID: 16585569.
      View in: PubMed   Mentions: 17     Fields:    Translation:AnimalsCellsPHPublic Health
    324. Anti-HER2/neu IgG3-(IL-2) and anti-HER2/neu IgG3-(GM-CSF) promote HER2/neu processing and presentation by dendritic cells: implications in immunotherapy and vaccination strategies. Mol Immunol. 2006 Feb; 43(6):667-76. Dela Cruz JS, Trinh KR, Chen HW, Ribas A, Morrison SL, Penichet ML. PMID: 15908002.
      View in: PubMed   Mentions: 3     Fields:    Translation:AnimalsCellsPHPublic Health
    325. Definition of an immunologic response using the major histocompatibility complex tetramer and enzyme-linked immunospot assays. Clin Cancer Res. 2006 Jan 01; 12(1):107-16. Comin-Anduix B, Gualberto A, Glaspy JA, Seja E, Ontiveros M, Reardon DL, Renteria R, Englahner B, Economou JS, Gomez-Navarro J, Ribas A. PMID: 16397031.
      View in: PubMed   Mentions: 17     Fields:    Translation:HumansCells
    326. Clinical trials with tumor antigen genetically modified dendritic cells. Semin Oncol. 2005 Dec; 32(6):556-62. Ribas A. PMID: 16338421.
      View in: PubMed   Mentions: 1     Fields:    Translation:HumansCells
    327. Genetically modified dendritic cells for cancer immunotherapy. Curr Gene Ther. 2005 Dec; 5(6):619-28. Ribas A. PMID: 16457651.
      View in: PubMed   Mentions: 13     Fields:    Translation:HumansAnimalsCells
    328. Antitumor activity in melanoma and anti-self responses in a phase I trial with the anti-cytotoxic T lymphocyte-associated antigen 4 monoclonal antibody CP-675,206. J Clin Oncol. 2005 Dec 10; 23(35):8968-77. Ribas A, Camacho LH, Lopez-Berestein G, Pavlov D, Bulanhagui CA, Millham R, Comin-Anduix B, Reuben JM, Seja E, Parker CA, Sharma A, Glaspy JA, Gomez-Navarro J. PMID: 16204013.
      View in: PubMed   Mentions: 141     Fields:    Translation:HumansCellsCTClinical Trials
    329. Combined immunostimulation and conditional cytotoxic gene therapy provide long-term survival in a large glioma model. Cancer Res. 2005 Aug 15; 65(16):7194-204. Ali S, King GD, Curtin JF, Candolfi M, Xiong W, Liu C, Puntel M, Cheng Q, Prieto J, Ribas A, Kupiec-Weglinski J, van Rooijen N, Lassmann H, Lowenstein PR, Castro MG. PMID: 16103070.
      View in: PubMed   Mentions: 77     Fields:    Translation:HumansAnimalsCells
    330. Broad antitumor protection by dendritic cells administered to CD8alpha knock out mice. Cancer Immunol Immunother. 2006 Jun; 55(6):663-71. Ribas A, Vo DD, Weeks DL, Comin-Anduix B, Schumacher LY, Garban HJ, McLean C, Yang J, Dissette VB, Peraza P, Owens SK, McBride WH, Glaspy JA, Economou JS. PMID: 16133107.
      View in: PubMed   Mentions: 1     Fields:    Translation:AnimalsCells
    331. Natural killer cells play a critical role in the immune response following immunization with melanoma-antigen-engineered dendritic cells. Cancer Gene Ther. 2005 Jun; 12(6):516-27. Wargo JA, Schumacher LY, Comin-Anduix B, Dissette VB, Glaspy JA, McBride WH, Butterfield LH, Economou JS, Ribas A. PMID: 15775996.
      View in: PubMed   Mentions: 10     Fields:    Translation:AnimalsCells
    332. Role of dendritic cell phenotype, determinant spreading, and negative costimulatory blockade in dendritic cell-based melanoma immunotherapy. J Immunother. 2004 Sep-Oct; 27(5):354-67. Ribas A, Glaspy JA, Lee Y, Dissette VB, Seja E, Vu HT, Tchekmedyian NS, Oseguera D, Comin-Anduix B, Wargo JA, Amarnani SN, McBride WH, Economou JS, Butterfield LH. PMID: 15314544.
      View in: PubMed   Mentions: 34     Fields:    Translation:HumansCellsCTClinical Trials
    333. Ionizing radiation affects human MART-1 melanoma antigen processing and presentation by dendritic cells. J Immunol. 2004 Aug 15; 173(4):2462-9. Liao YP, Wang CC, Butterfield LH, Economou JS, Ribas A, Meng WS, Iwamoto KS, McBride WH. PMID: 15294960.
      View in: PubMed   Mentions: 45     Fields:    Translation:HumansAnimalsCells
    334. Surveillance of the eye and vision in a clinical trial of MART1-transformed dendritic cells for metastatic melanoma. Control Clin Trials. 2004 Aug; 25(4):400-7. Gordon LK, Ribas A, Nusinowitz S, Butterfield LH, Glaspy JA, Economou JS, Straatsma BR. PMID: 15296814.
      View in: PubMed   Mentions: 2     Fields:    Translation:HumansCellsPHPublic Health
    335. Human dendritic cell maturation by adenovirus transduction enhances tumor antigen-specific T-cell responses. J Immunother. 2004 May-Jun; 27(3):191-200. Schumacher L, Ribas A, Dissette VB, McBride WH, Mukherji B, Economou JS, Butterfield LH. PMID: 15076136.
      View in: PubMed   Mentions: 23     Fields:    Translation:HumansCells
    336. Enhanced tumor responses to dendritic cells in the absence of CD8-positive cells. J Immunol. 2004 Apr 15; 172(8):4762-9. Ribas A, Wargo JA, Comin-Anduix B, Sanetti S, Schumacher LY, McLean C, Dissette VB, Glaspy JA, McBride WH, Butterfield LH, Economou JS. PMID: 15067052.
      View in: PubMed   Mentions: 9     Fields:    Translation:HumansAnimalsCells
    337. T-cell responses to HLA-A*0201 immunodominant peptides derived from alpha-fetoprotein in patients with hepatocellular cancer. Clin Cancer Res. 2003 Dec 01; 9(16 Pt 1):5902-8. Butterfield LH, Ribas A, Meng WS, Dissette VB, Amarnani S, Vu HT, Seja E, Todd K, Glaspy JA, McBride WH, Economou JS. PMID: 14676113.
      View in: PubMed   Mentions: 50     Fields:    Translation:HumansCellsCTClinical Trials
    338. Current developments in cancer vaccines and cellular immunotherapy. J Clin Oncol. 2003 Jun 15; 21(12):2415-32. Ribas A, Butterfield LH, Glaspy JA, Economou JS. PMID: 12805342.
      View in: PubMed   Mentions: 55     Fields:    Translation:HumansAnimals
    339. Determinant spreading associated with clinical response in dendritic cell-based immunotherapy for malignant melanoma. Clin Cancer Res. 2003 Mar; 9(3):998-1008. Butterfield LH, Ribas A, Dissette VB, Amarnani SN, Vu HT, Oseguera D, Wang HJ, Elashoff RM, McBride WH, Mukherji B, Cochran AJ, Glaspy JA, Economou JS. PMID: 12631598.
      View in: PubMed   Mentions: 77     Fields:    Translation:HumansCellsCTClinical Trials
    340. Determinant spreading and tumor responses after peptide-based cancer immunotherapy. Trends Immunol. 2003 Feb; 24(2):58-61. Ribas A, Timmerman JM, Butterfield LH, Economou JS. PMID: 12547500.
      View in: PubMed   Mentions: 36     Fields:    Translation:HumansCells
    341. Immunosuppressive effects of interleukin-12 coexpression in melanoma antigen gene-modified dendritic cell vaccines. Cancer Gene Ther. 2002 Nov; 9(11):875-83. Ribas A, Amarnani SN, Buga GM, Butterfield LH, Dissette VB, McBride WH, Glaspy JA, Ignarro LJ, Economou JS. PMID: 12386826.
      View in: PubMed   Mentions: 3     Fields:    Translation:HumansAnimalsCells
    342. Immunotherapy of hepatocellular carcinoma. Expert Opin Biol Ther. 2002 Feb; 2(2):123-33. Butterfield LH, Ribas A. PMID: 11849113.
      View in: PubMed   Mentions: 8     Fields:    Translation:HumansAnimalsCells
    343. Cancer immunotherapy using gene-modified dendritic cells. Curr Gene Ther. 2002 Feb; 2(1):57-78. Ribas A, Butterfield LH, Glaspy JA, Economou JS. PMID: 12108974.
      View in: PubMed   Mentions: 11     Fields:    Translation:HumansAnimalsCells
    Antoni's Networks
    Concepts (815)
    Derived automatically from this person's publications.
    _
    Co-Authors (86)
    People in Profiles who have published with this person.
    _
    Similar People (60)
    People who share similar concepts with this person.
    _
    Same Department
    Search Department
    _